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ABSTRACT
Allogeneic hematopoietic chimerism leading to central tolerance has significant
therapeutic potential. Establishment of hematopoietic chimerism created by stem cell
transplantation has been shown to prevent and cure a number of autoimmune diseases
and induce the most robust and long-lasting form of transplantation tolerance known.
However, the realization of the vast clinical potential of hematopoietic chimerism for
induction of transplantation tolerance has been impeded by the toxicity of the host
conditioning regimen and the development of graft-versus-host disease (GVHD). This
thesis describes the development of stem cell transplantation protocols that 1) reduce the
host conditioning regimen; and 2) abrogate the development of GVHD. When applied to
the treatment of autoimmune diabetic NOD mice, a model of type 1 diabetes, stem cell
transplantation was able to 3) prevent autoimmune recurrence; and 4) permit curative
pancreatic islet transplantation.
I first describe a tolerance-based stem cell transplantation protocol that combines
sub-lethal irradiation with transient blockade of the CD40-CD154 costimulatory pathway
using an anti-CDl54 antibody. With this protocol, I established hematopoietic chimerism
in BALB/c mice transplanted with fully allogeneic C57BL/6 bone marrow. All chimeric
mice treated with anti-CDl54 antibody remained free of graft VS. host disease (GVHD)
and accepted donor-origin but not third pary skin allografts. It was similarly possible to
create allogeneic hematopoietic chimerism in NOD/Lt mice with spontaneous
autoimmune diabetes. Pancreatic islet allografts transplanted into chimeric NOD/Lt mice
were resistant not only to allorejection but also to recurrence of autoimmunity. I conclude
that it is possible to establish robust allogeneic hematopoietic chimerism in sub-lethally
irradiated mice without subsequent GVHD by blocking the CD40-CD 154 costimulatory
pathway using as few as two injections of anti-CDl54 antibody. I also conclude that
chimerism created in this way generates donor-specific allograft tolerance and reverses
the predisposition to recurrent autoimmune diabetes in NOD/Lt mice, enabling them to
accept curative islet allografts.
In order to fuher reduce the impediments associated with the implementation of
allogeneic hematopoietic chimerism as a therapeutic modality, I adapted a costimulation
blockade-based protocol developed for solid organ transplantation for use in stem cell
transplantation. The protocol combines a donor-specific transfusion (DST) with anti-
CD 154 antibody to induce peripheral transplantation tolerance. When applied to stem
cell transplantation, administration of DST, anti-CDl54 antibody, and allogeneic bone
marrow led to hematopoietic chimerism and central tolerance with no myeloablation (i.
no radiation) and no GVHD in 3 different strains of mice. The development of donor-
specific tolerance in this system was shown to involve deletion of both peripheral host
alloreactive CD8+ T cells and nascent intrathymic alloreactive CD8+ T cells. In the
absence of large numbers of host all ore active CD8+ T cells, the cell transfusion that
precedes transplantation need not be of donor-origin, suggesting that both allo-specific
and non-allo-specific mechanisms regulate engraftment. Agents that interfere with
peripheral transplantation tolerance partially impair establishment of chimerism. I
conclude that robust allogeneic hematopoietic chimerism and central tolerance can be
established in the absence of host myeloablative conditioning usmg a peripheral
transplantation tolerance protocol.
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CHAPTER I
GENERAL INTRODUCTION
Introduction
The modem era of transplantation has seen incredible advances due to the
discovery of immunosuppressive drgs, Since the pioneering works of the 1950s
transplantation of a number of solid organs has become very successful and life-saving
for almost all patients involved, But, even as the effectiveness and potency of the
immunosuppressive drgs continually improve, the serious side effects that come with
their usage are stil ever present. These drgs induce a generalized suppression of the
immune system in the patient that prevents rejection of the transplanted organ, but their
ability to non-specifically affect the whole immune system is also their major toxicity.
The field of transplantation is approaching a new era in which immunosuppressive drgs
may no longer be needed. Researchers are now concentrating on targeting specific
immune cells rather than inducing a generalized suppression of the patient' s immune
system. The most promising alternative to the use of immunosuppressive drugs for
transplantation is the induction oftransplantation tolerance.
The clinical definition of transplantation tolerance is the surival of foreign tissue
in normal recipients in the absence of immunosuppression, For more then 50 years , the
most robust and long-lasting form of transplantation tolerance has been the induction of
allogeneic hematopoietic chimerism through stem cell/one marrow transplantation, The
'''\
establishment of the chimeric state is thought to subsequently utilize the mechansm for
deleting self-reactive lymphocytes (central tolerance) to also delete alloreactive T cells.
In addition to the induction of allogeneic chimerism, stem cell transplantation has
become an established clinical treatment for fatal disorders of the lymphohematopoietic
system. Studies in both humans and animals have also demonstrated the ability of stem
cell transplantation to cure several autoimmune diseases. In autoimmune disorders such
as type I diabetes mellitus that require not only cure of the autoimmune process but also
the replacement of damaged organ, allogeneic chimerism offers the possibility of
achieving both goals simultaneously. The work presented in this thesis seeks to achieve
these goals by creating clinically useful protocols and identifying mechanisms
responsible for the generation of hematopoietic chimerism and the induction of tolerance.
. .
History of Transplantation
From ancient times to the immunosuppression era
The earliest recorded attempts at tissue transplantation date back thousands of
years. An ancient Chinese legend records the medical miracles of two famous surgeons
Pien Ch' iao and Hua T' , durng 2 century B, They were reputed to have
successfully transplanted tissues and organs, including the intricate hear, without
inflcting pain to the patients, But these stories have been designated as more myth than
history. However, the oldest record of successful transplantation surgeries can be found
in the Sanskrt text of India, the Sushruta Samhita written more than 2 000 years ago.
The author, Sushrta, is described taking autogeneous pedicled grafts from the forehead
neck, and cheek to restore mutilations of the nose, ear, and lip. The work of Shushrta is
one of the greatest of its kind in the Sanskrt literature and is of special importance in the
history of surgery due to its emphasis on the need for extensive training to produce
skilful surgeons (1). Not to be outdone by the East, the West also boasted feats of
transplantation marvels, Among the classic legends, the Saints Cosmos and Damian were
reputed to have transplanted the leg of a dead Moor to a patient whose leg had been
amputated. This famous legend was a great favorite among medieval artists (1).
The modem revival of transplantation began with John Hunter (1728- 1793), the
father of experimental surgery, who moved the surgical field from a mechanical ar to an
experimental science. He believed that all living substances had the disposition to unite
when brought into contact with one another and, thus , helped establish the scientific basis
;f"
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of modem surgery (2). But it wasn t until the early 1900s that modem transplantation
emerged as a promising field with the pioneering work of Nobel laureate Alex Carel
who developed vascular suture techniques that are still used for transplantation today,
With this technique, surgeons were finally able to transplant a variety of organs, such as
the kidneys, the hear, the thyroid and parathyroids , and the ovaries (3). But the kidney
became the pilot organ for research on transplantation because it could be removed easily
and transplanted quickly. They were also convenient because excretory capacity allowed
assessment of the transplant's renal fuction with simple serial observations. However
the continued failure to achieve allograft survival by the surgeons severely diminished the
field of tissue transplantation by the 1920s. It would take 20 years and a world war for
interest in the field to make a comeback.
The basic "laws of transplantation" were known as far back as 1912, as published
by Georg Schone (4). His observations of the general rules of transplantation are still
valid to this day:
1) auto grafts generally succeed
2) allografts usually fail
3) allograft rejection is not immediate, but delayed (takes time)
4) rejection of second graft is accelerated if recipient previously rejected the graft from
same donor
Interestingly, most of his observations were based on results from tumor research that
were expanded to encompass skin and other organs (4). It was not until World War II
that the immunologic basis for allograft failures began to be understood. Peter Medawar
iTj
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a zoologist working in England, became interested in the problems of skin grafting after
it was realized that seriously burned pilots required extensive medical procedures to
surive, In his classic experiments, Medawar observed that the surival of autologous
and allogeneic skin grafts on a human bum victim (5) and rabbits (6) experimentally
supported the "laws of transplantation" observed decades earlier. Medawar s subsequent
research helped establish the concept of immunological factors participating in graft
rejection, thus bringing the field of immunology into transplantation.
In the next decade, the first successful kidney transplantation was performed
between monozygotic twins in 1954 by Joseph Muray, who was later awarded the Nobel
Prize for this achievement (1). Despite the success of this and other transplants between
monozygotic twins, transplanting tissues between genetically disparate patients remained
largely unsuccessful. A number of important observations in the mid- 1950s helped
elucidate the role of the immune system in the rejection of transplanted tissues. Rupert
Billngham, Leslie Brent, and Peter Medawar reported the use of lymphoid cells from
sensitized donors to "adoptively transfer" immunity against skin grafts and other tissues
in the mouse (7). Other researchers also demonstrated that lymphocytes can directly
attack transplanted tissue even in the absence of antibody (1). These studies led to the
recogntion that cellular, rather than humoral, factors were actively involved in
transplantation rejection. These results also led to the recognition that regulation of these
cellular factors through ImmunosuppressIOn the lawsmight overcome
transplantation
" .
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Effective drgs to alter the immune system were not available at that time, so the
first attempts at immunosuppression involved total body irradiation. Although irradiation
proved to be effective in preventing the rejection of the grafts, it led to a very high
mortality rate. In the early 1960s, Roy CaIne introduced the first line of
immunosuppressive drugs, 6-mercaptopurine, into clinical practice after successfully
transplanting kidneys in dogs. This advance was followed soon thereafter by the
development of a longer acting and less toxic derivative of the drug, azathioprine.
Durng this decade, many other organs were transplanted for the first time: the liver by
Thomas Starzl in 1963 , the lung by James Hardy in 1963 , the pancreas by Richard
Lilehei in 1966 , and the hear by Chrstiaan Barnard in 1967 (1).
Organ transplantation from unrelated donors was now possible, but graft surival
remained poor, with the best center achieving I-year surival rates of 50% for cadaver
kidney transplants, Then, the chance discovery of a promising agent from a fugal strain
changed dramatically the success rate for organ transplantation. Cyclosporine A
discovered by Jean-Francois Borel in 1972 , was found to disrupt T lymphocyte activation
by blocking the production of interleukin-2 (IL-2). The use of cyclosporine dramatically
improved graft survival and quickly became the standard immunosuppression in
transplant recipients. Over the last decade additional immunosuppressive agents have
been discovered such as tacrolimus (FK-506), which inhibits both IL-2 production and
IL-2 receptor expression, and sirolimus (rapamycin). Biological immunosuppressants
have also come onto the field such as anti-thymocyte globulin (AT G) and OKT-3 anti-
CD3 monoclonal antibody (mAb) that target the immune cells.
Problems with Immunosuppression
The achievements transplantation after the introductionorgan
immunosuppressive drugs have been amazmg. Over the past two decades the
development of new immunosuppressive drugs and a better understanding of how they
work have led to marked improvement in patient survival and short-term graft survival.
The I-year survival of cadaveric renal allografts in the pre-cyclosporine era was 65%,
whereas it now exceeds 80-85% (3;8). Similar success has been achieved in the
transplantation of other major solid organs such as the liver, hear, lung and pancreas,
But in spite of this success, immunosuppressive drugs have major residual problems that
affect the life and livelihood of the patients.
There are now a number of different immunosuppressive drugs available for
transplanted patients ranging from anti-metabolites such as azathioprine and
mycophenolate mofetil, to calcineurn inhibitors such as cyclosporine and tacrolimus,
But all these drugs are toxic to some degree to both the patient and the transplanted
tissue. Anti-metabolites have been associated with bone marow suppression and liver
failure (9). The well known adverse effects of glucocorticoids include hypertension
hyperlipidemia, diabetes mellitus and osteopenia (10). Even though calcineurn
inhibitors, specifically cyclosporine, revolutionized transplantation with their potent
immunosuppressive activity, they have the most toxic effects among the different drgs.
The most important are the neurologic, endocrinologic, hepatic, and renal toxicities.
Patients can experience tremors and seizures due to affects on the nervous system and as
mm:y as 85% of renal transplant recipients wil be treated for hypertension because of
cyclosporine A therapy (11), As transplant recipients surive longer, post-transplant
diabetes mellitus (PTDM) has emerged as a major adverse effect of immunosuppressants,
Corticosteroids have been shown to induce insulin resistance, while cyclosporine and
tacrolimus are thought to inhibit insulin secretion and production, and also induce
peripheral insulin resistance (12), Biological immunosuppressants, such as anti-
lymphocyte seru (ALS) and A TG, do not have as much toxicity as their chemical
counterparts, but they do significantly impair cell-mediated immunty resulting in
opportunistic infections and an increased frequency of malignancies. The incidence of
cytomegalovirus (CMV) infection was observed to be twice as high in liver allograft
recipients treated with ALS compared to those treated with conventional
immunosuppression (13). Another problem associated with these polyclonal antibodies
is that there is inter-batch variation in their potency making effective treatment diffcult.
Another major problem associated with immunosuppressive drgs is "chronic
rejection." Even though the overall I-year survival for cardiac transplantation is 79%,
the patient half-life (time to 50% surival) is only 8,7 years. The decline in survival is
almost a straight line from year one through year 14 with a constant mortality rate of 4%
per year (14), The outlooks are very similar with the other major organs. A majority of
transplanted grafts wil fuction for a year, but a steady decline in surival can be seen as
the years accumulate. The pathophysiology of chronic allograft rejection is poorly
understood, It is widely acknowledged that both immunologic and nonimmunologic
factors are likely to playa role in the pathogenesis (15),
The key mechanism of immunosuppressive drugs is their ability to block
lymphocyte fuctions, but their caveat is that it is a generalized block that affects the
whole immune system. People with an impaired immune system are generally more
susceptible to virus infections than those who are fully immunocompetent. Patients with
T cell deficiencies are more liable to experience infections with viruses, as well as
intracellular bacteria, fungi and some protozoa. Infection with CMV is extremely
common after transplantation, particularly in recipients who are seronegative for CMV
and who receive seropositive organs. Because of the heightened immunosuppression and
the risk of receiving seropositive grafts, endogenous viruses such as the herpesviruses
(i. e., CMV , EBV) and hepatitis viruses are commonly associated with transplant patients
(16), Without a fully competent immune system, transplant patients depend on effective
anti-viral or anti-bacterial drgs to combat any deadly microorganisms. But even though
most infections can be treated, highly drg-resistant organisms have been detected with
increasing frequency (17). The loss in the drgs ' effectiveness would detrimentally
affect the lives of these patients,
The increasing numbers of successful long-term transplant patients has
heightened concern about the development of malignancies. The increased incidence of
neoplastic diseases in transplant recipients is well recognized, The risk of
lymphoproliferative diseases and skin cancer after transplantation ranges between 2 to 25
times the normal expectations (18), with the latter being the most common, The most
important discoveries of the past two decades in cancer epidemiology relate to the
carcinogenic effects of infectious pathogens. There is good evidence that Epstein-Barr
virus (EBV) is responsible for most lymphoproliferative diseases in immunosuppressed
patients (19). Infection with the papilomavirus has also been thought to cause many of
the cases of skin cancer in transplant recipients (16),
Another major issue is recurrence of disease in a successfully transplanted organ.
Tissue-specific autoimmune diseases, like type I diabetes melltus , can reoccur because
of the persistent existence of destructive lymphocytes and antibodies in the host. 
diabetic patient transplanted with both kidney and insulin-producing pancreas from an
identical twin donor wil indefinitely accept the kidney graft without immunosuppression
due to lack of an alloresponse in the host because of the complete MHC match, But the
insulin-producing beta cells in the pancreatic graft wil be destroyed because of the
continued existence of autoreactive lymphocytes (autoimmune recurrence) (20),
Relatively high amounts of immunosuppressants are needed not only to prevent
allorejection, but to also break the autoimmune memory. Unfortately, standard
regimens of immunosuppressive drgs were not effective for islet transplantation in
diabetic patients for many years. Recently, however, a new protocol termed the
Edmonton protocol" has attained a high success rate for successful islet transplantation
in diabetic patients (21), But fuher study is needed to determine if disease recurrence
has truly been blocked in these cases, In diabetic animal models transplanted with
syngeneic pancreatic islets and treated with a similar immunosuppressive therapy, initial
graft survival is attained but eventually the islet grafts are rejected due to the persistent
autoimmune response (22),
Imunosuppressive drgs have made an incredible impact in the transplantation
field, but their deleterious side-effects have limited the full curative potential of organ
transplantation, In an effort to find alternatives to generalized immunosuppression
intense research is now focused on the induction of transplantation tolerance,
o;(!('i'
Mechanisms of Tolerance
Definition of Tolerance
Tolerance is a process that comprises the whole repertoire of immune cells and
regulatory pathways to prevent reactivity against a specific antigen (or antigens). The
most basic concept of tolerance is the elimination or neutralization of lymphocytes
specific for self-peptides and self-MHC to prevent autoimmunity (self-tolerance). This
process involves both "central tolerance" and "peripheral tolerance" mechansms. With
the introduction of modem tissue transplantation, the term "transplantation tolerance" has
emerged with two complementary definitions. It is defined clinically, or functionally, as
the surival of foreign tissue in normal recipients in the absence of immunosuppression,
It is also defined immunologically as the complete absence of a detectable immune
response to a functional graft in the absence of immunosuppression (23). The rationale
for this distinction is that experimental studies have shown that allogeneic grafts can
surive and function in vivo even when donor-specific kiling is observed using in vitro
assays (split tolerance) (24). Additionally, prolonged survival of allografts has been
demonstrated despite the presence of cellular infitration (25), Since the success of tissue
transplantation is determined by the survival of the graft rather than the cellular
interactions involved, the fuctional definition is used more widely. In order to better
understand how to induce transplantation tolerance, one has to first understand self
tolerance, By manipulating Mother Nature s mechanism for tolerance against self, we
can, expand that tolerance to include foreign donors. The next few chapters will highlight
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the mechanisms by which self tolerance is maintained in the body through central and
peripheral tolerance mechanisms.
Central T-Cell Tolerance
Central tolerance refers to a tolerant state established primarily in the thymus
through clonal deletion of developing antigen-reactive T cells. Central tolerance is the
principal mechanism that eliminates autoreactive T cells and generates a state of self-
tolerance. The human body can generate a diverse repertoire of T cells based on random
gene rearrangement of the T cell receptor (TCR) DNA combined with junctional
diversity. These "uneducated" T cells would not only recognize foreign antigen on self-
MHC molecules, but would also recognize self antigens leading to autoimmunity. The
potential antigenic diversity of T cells is tremendously reduced during matuation by a
selection process in the thymus that allows only MHC-restrcted (positive selection) and
non-self-reactive (negative selection) T cells to surive.
T cell precursors arising from bone marrow stem cells migrate to the cortex of the
thymus where they proliferate into immatue CD4 CD8+ thymocytes expressing T cell
receptors (TCR) on the cell surface. Only thymocytes that express a fuctional TCR can
survive and proceed to the next stage of development. These immature T cells are now
able to interact with antigen-presenting cells (APC) that express self-MHC molecules
bearng self-peptides (26). This MHC-peptide complex is recognzed by the TCR, and
signals transduced through the TCR constitute a key element in selection of the
developing thymocytes. The current understanding is that the interaction of immature
double-positive thymocytes with thymic epithelial cells, mediated by MHC-restricted T-
cell receptors, allow the cells to receive a protective signal permitting their survival, a
process termed positive selection (27). In contrast, cells whose receptors are not MHC
restricted would not interact with the epithelial cells and would consequently not receive
the protective signal , thus leading to their death by apoptosis , commonly referred to as
death by neglect" (28;29).
The population of MHC-restricted thymocytes that survive positive selection
comprises some cells with low-affinity receptors for self-antigens and other cells with
high-affinity receptors, The latter group of cells undergoes negative selection by
interacting with bone marow-derived APCs comprised mostly of dendritic cells and
macrophages (30;31), During negative selection, thymocytes bearing high-affnity
receptors for self-antigen plus self-MHC molecules interact with APCs bearng class I
and class II MHC molecules and undergo rapid apoptotic cell death (32-35). Tolerance
to self-antigens is thereby achieved by eliminating autoreactive double-positive
thymocytes and only allowing matuation of T cells that bear low or moderate affnity to
a self-MHC-peptide complex. The process of clonal deletion in the thymus has been
studied experimentally by following the intrathymic development of specific populations
of T cells that express unique TCR V sequences or transgenic TCR specific for a known
peptide antigen;
The mechanism involved in clonal deletion to induce self tolerance postulates that
all self-reactive T cells are eliminated before their migration into the periphery (34;36).
Therefore, based on this mechanism, it can be hypothesized that introduction of
transplantation antigen into the thymus should result in the selective deletion of all T cells
reactive to that antigen and should therefore induce tolerance (23). Several potent
protocols for inducing transplantation tolerance have taken successful advantage of this
process in murine models, such as intrathymic injections (37;38) and allogeneic
chimerism (39;40). This subject will be discussed below with a major emphasis on
induction of allogeneic hematopoietic chimerism.
Peripheral T-Cell Tolerance
Peripheral tolerance refers to a tolerant state that is primarly established outside
of the thymus and its selection process. Even though intrathymic central tolerance is very
efficient, it does not delete all T cells that recognize self-antigen/HC complexes. It is
evident that there are some autoreactive T cells circulating in the peripheral tissues, but in
most individuals, they do not lead to the expression of autoimmune disease (41 ;42),
Thus, it appears that there are peripheral mechanisms that control the destructive
potential of T cells that have escaped negative selection in the thymus. It is believed that
peripheral tolerance is induced and maintained by a series of distinct but interrelated
mechanisms (23). The major mechanisms involved are clonal deletion, anergy, and
immune suppression/regulation. Other processes such as immune deviation, T cell
exhaustion, ignorance, and immune privileged sites are important, but are beyond the
scope of this thesis and are not discussed fuher.
Clonal Deletion
Intrathymic clonal deletion has long been recognized as a primary mechanism of
tolerance induction to self antigens, but clonal deletion of peripheral T cells has recently
also been recognized to be important in the induction of tolerance. Peripheral deletion 
T cells was originally identified in systems in which strong responses against either
superantigens (43-45) or conventional antigens (46;47) resulted in the disappearance of
responding T cells. More recently, experimental studies using self antigens have
demonstrated the deletion of self-reactive T cells in the periphery (41 ;42;48).
It has been suggested that apoptosis via the Fas/FasL pathway may play an
important role in peripheral T cell deletion and tolerance (41 ;49). Surface expression of
Fas (CD95) is upregulated on many activated T cells. The interaction between Fas and
its counter-receptor FasL (CD95L) leads the cell expressing Fas to undergo programed
cell death by apoptosis (50). This process is thought to be important in the down-
regulation of T cell responses (51) as evidenced by the lymphoproliferative disorders in
Fas- or FasL-deficient mice and humans. So, not only are Fas and FasL important in
peripheral deletion to regulate T cell homeostasis, they may also be crucial in the deletion
of self-reactive T cells in the periphery (52).
Anergy
Anergy is a state in which T cells stimulated by TCR engagement are functionally
unesponsive and refractory to activation (53), In addition to the primary signal
generated by the TCR/C complex , T cells require a second co stimulatory signal (i.
CD28/B7 interaction) to become optimally activated. Further overview of this process
wil be discussed below in the section entitled "Co-stimulatory blockade and tolerance
induction," Anergy is readily induced in vitro by T cells binding to their specific ligands
in the absence of co stimulation (54). Anergic cells are characterized by the inability to
produce IL-2 upon secondar challenge with antigen in conjunction with optimal
co stimulation. However, a common characteristic of anergic cells is their ability to
reverse their unesponsiveness and proliferate in response to exogenous IL-2 (55). But
anergy is not automatically maintained once induced; a continual presence of antigen is
required to maintain their unresponsive state (56;57).
Induction of anergic T cells in vivo has been demonstrated in mice after
administration of tolerizing doses of bacterial superantigens (sAgs), Mls- l a, and peptide
antigens that do not cause deletion of antigen-reactive T cells (58). A number of
differences have been shown between T cells anergized in vivo and T cell clones
anergized in vitro. The former has been found tobe more resistant to stimulation with
exogenous IL-2 than the latter (59). This difference may reflect the constitutive
expression of high affnity IL-2 receptors on the T cell clones , but not on normal T cells
(58). But a common feature between the in vivo and in vitro anergized T cells is their
profound defect in the expression of CD154 (60). CD 154 is expressed mostly on
activated CD4+ T cells and plays a critical role in delivering costimulatory signals for T
cell activation (61). More information on this co stimulatory molecule will be discussed
below.
T cell anergy has been suggested to play an important role in allograft tolerance in
many systems. However, peripheral tolerance relying primarly on anergy may be
unstable due to their readily reversible natue and the reliance on continued antigen
stimulation to maintain the anergic state. Such tolerance may be easily broken through
exogenous stimuli. For example, it has been demonstrated that infections and consequent
inflamation can break anergy-dependent tolerance (62;63),
Immune regulation suppression
Lymphocyte subpopulations that were able to suppress immune responses were
first described over thirty years ago (64). However, the inability to clone these
suppressor T cells and to identify any specific cell markers led researchers to lose interest
in this entire field of study in the 1980s (65;66). But recently there has been a resurgence
of interest in this area after Sakaguchi and his colleagues demonstrated that the
interleukin-2 receptor (IL-2) a-chain molecule, CD25 , can be used as a marker for cells
with suppressive activity (67;68). They showed that a minor population ( 10%) of CD4
T cells expressing CD25 is important for the control of autoreactive T cells in vivo.
Subsequently, other groups have identified additional cell populations that also have
suppressive properties. The majority of regulatory T cells identified to date are within
the CD4+ population, but other T cell subsets, such as CD8 , CD8 CD28- , and TCR CD4-
CD8- have also been shown to contain cells with regulatory capacities (69-72). Although
the term ' regulatory T cell' has replaced the term ' suppressor T cell' in the immunology
literature, the former can mean either the enhancement or suppression of the immune
response. In the transplantation tolerance field where specific down-regulation of
immune responses is desired, I will use the term regulatory T cells to describe their
suppressive activity in this thesis,
Studies in vitro have shown that the CD4 CD25+ regulatory cells do not
proliferate in response to stimulation unless exogenous IL-2 is added to the culture (73-
75), Furher studies have shown that suppression occurs only when the regulatory cells
are stimulated through their T cell receptor (TCR) and are in direct contact with the
population being regulated (73;76), The main mechanism of suppression seems to be the
inhbition ofIL-2 production in the responder population.
The role of cytokines in the fuction of the CD4 CD25+ regulatory cells remains
to be defined. Regulatory cells from normal mice have been shown to transcribe IL-
IL- I0 and TGF-p genes more actively than the reciprocal CD4 CD25- population (67).
Additional studies, however, have shown that neutralization of these cytokines has little
effect on suppression in vitro (76). In vivo experiments have been more convincing in
demonstrating the role cytokines may have in regulatory fuctions. IL- I0 production by
CD4 CD25+ cells has been found to be important in regulation of cytokine production, as
regulatory cells from IL- l 0 knockout animals do not show regulatory effects in vivo (77).
Blockade of IL- I0 and TGF-p using monoclonal antibodies also has been demonstrated
to prevent regulation in many disease models such as ulcerative colitis (78;79),
experimental autoimmune encephalomyelitis (80), autoimmune nephrtis (81), and
autoimmune thyroiditis (82).
Regulatory cells are also important in transplantation tolerance, The first
suggestion for the existence of regulatory cells came from studies on neonatal tolerance,
In neonates injected with allogeneic donor bone marrow, not only is the donor graft
tolerated, but the tolerance cannot be broken by an infusion of non-tolerized syngeneic
lymphocytes (83), This result suggested the existence of an active suppressive
mechanism. Further indications of the importance of regulatory cells in transplantation
come from findings that alloreactive cells are still present in animals bearing intact grafts.
This was demonstrated by the detection of in vitro proliferation and cytotoxic activity
against donor graft antigens (83;84). The concept of active immune regulation in the
periphery has been around for many years, but identifying the specific cells involved in
the action proved to be diffcult. It was not until the discovery of the CD25+ molecule on
CD4+ cells as a marker for regulatory cells that researchers were able to target the cell
population involved in transplantation. These cells have now been identified in mice
with long-term surviving cardiac and pancreatic islet allografts (85;86) and have been
shown to also suppress the rejection of allogeneic skin grafts (87). Additionally, cells
within the CD4 CD45RB1ow population in mice have recently been shown to possess
regulatory properties in transplantation as adoptive transfer of these cells are able to
prevent CD4 CD45RBhigh-mediated rejection of skin allografts (85). The importance of
IL- , TGF- and CTLA-4 in transplantation tolerance by regulatory cells has also been
demonstrated in mice and rats (85-88).
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Type Diabetes Mellitus: An Autoimmune Disease
Autoimmunity
As described above, the fundamental definition of tolerance is the elimination or
neutralization of lymphocytes specific for self-peptides and self-MHC complexes by
mechanisms accomplished in both the thymus and the peripheral tissues. The processes
involving self-tolerance are ongoing recurrng events that when interrpted by genetic
and/or environmental factors can lead to expression of autoimmunity. Any defect in the
tolerance process, from thymic selection to production of regulatory cells, can trigger
autoimmunty.
Clinically, autoimmunity can be defined using three criteria: 1) direct evidence
from transfer of disease by antibodies or immune cells; 2) indirect evidence based on
reproduction of the autoimmune disease in experimental anmals; and 3) circumstantial
evidence from clinical clues such as pathology and familial inheritance (89). Based on
these criteria, more than 40 human diseases can be classified as autoimmune disorders.
This thesis work wil concentrate on one of those disorders, type 1 diabetes mellitus , but
it is expected that the work accomplished in this project wil be applicable to the
treatment of other autoimmune diseases.
Type 1 , or juvenile, insulin-dependent diabetes is caused by an absolute
deficiency in the production of insulin as a result of pancreatic beta cell destrction and
consequent hyperglycemia, About one milion people in the United States suffer from
this disease comprising 10- 15% of the total diabetic population (90). Since the
discovery of insulin, deaths related directly to the absolute absence of insulin (diabetic
ketoacidosis) have markedly decreased. But despite tight control of glucose levels , most
patients with diabetes develop end-organ complications, including renal failure
proliferative retinopathy, peripheral neuropathy, and premature coronary disease (91).
The current consensus is that the islet beta cells are destroyed by an autoimmune
response mediated by T lymphocytes that react specifically to one or more beta cell
proteins. There are several lines of evidence to support the concept that type 1 diabetes is
a T cell-mediated autoimmune disease. a) The presence of mononuclear cell infitrate
(insulitis) in the islets. b) A strong linkage between type 1 diabetes and certain alleles of
the major histocompatibility complex (MHC) , c) Autoantibodies that react with islet cell
autoantigens. d) Imunosuppressive and immunomodulatory agents can slow the
progressive destrction of the beta cells. e) Disease can be transferred through
transplantation of bone marow cells or immune cells from diabetic donors to non-
diabetic recipients. t) Disease recurrence destroys insulin-producing transplant from non-
diabetic identical twin (91;92),
Approaches to Treat Autoimmune Diseases
The primary treatment for most patients with type 1 diabetes , which has remained
essentially the same for the last 80 years, is injection of exogenous insulin. But, as
mentioned previously, insulin injections are not effective enough for the long-term well-
being of the patient due to their inability to maintain the metabolic balance of glucose.
Based on the aforementioned lines of evidence supporting the concept that type 
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diabetes is a disease in which the host's immune system inappropriately attacks healthy
insulin-secreting beta cells, new strategies for therapeutic treatment are being developed
and tested. Since the underlying cause of type 1 diabetes is the immune system, one such
therapy takes the form of immunosuppression, Although directed at the abnormal
immune fuction that underlies type 1 diabetes, this form of therapy is non-specific and
consequently associated with toxic side effects and, until recently (21 ), with suboptimal
clinical results. Additionally, in the case of type 1 diabetes, immunosuppression alone
would only be effective if the patient stil possessed suffcient beta-cell mass for adequate
metabolic balance. Clinical trials to test this theory showed that 30-50% of recently
diagnosed patients who received the immunosuppressant cyclosporine A underwent
remission from diabetes (93;94). But the patients displayed many of the toxic side-
effects of the drug and remission was dependent on quick treatment after onset of the
disease. Other forms of therapy for those patients fortnate enough to stil retain some
beta cell fuction include aggressive insulin treatment (95;96) and FcR non-binding
humanzed antibodies to CD3 (hOKT3) (97).
Autoimmune diseases, including type 1 diabetes, are all believed to involve
lymphohematopoietic lineages descended from plurpotent hematopoietic stem cells that
fuction abnormally. In both animal models and in humans , autoimmune diabetes has
been shown to be transferred by bone marrow stem cells from diabetic donors (92;98).
The replacement of these abnormal stem cells by cells derived from a normal population
is the premise underlying stem cell transplantation therapy, The treatment is designed to
replace host immune cells that have native or acquired autoimmunity and/or replace
mlssmg or defective regulatory cell populations that are necessary to keep the
autoreactivity in check. Laboratory studies have shown that development of autoimmune
diabetes can be prevented if bone marrow cells from non-autoimmune-prone strains are
transplanted into pre-diabetic NOD/Lt mice (99; 1 00). More recently, Beihack et al. have
shown that purfied hematopoietic stem cells obtained from bone marrow can also stop
the development of hyperglycemia in NOD mice even with significant. levels of NOD T
cells still circulating in the host (101).
In animal models, literally dozens of therapies prevent type 1 diabetes, but very
few can cure established and advanced forms of the disease (102), Two major obstacles
must be overcome to fully treat autoimmune diabetes. Firstly, in the advanced form of
the disease the destroyed pancreatic islet beta cells must be replaced. Since the most
likely donors will be genetically disparate, an allo-tolerant state must be achieved to
prevent the rejection of the transplanted islets or pancreas. Secondly, the patient has to
overcome recurent autoimmunity, Even syngeneic transplantation of replacement tissue
is unsuccessful because of the continued presence of the autoreactive T cells that initially
destroyed the target tissue (20). Stem cell transplantation offers the possibility of
overcoming both major obstacles simultaneously. Hematopoietic stem cell chimerism
has been shown to reverse the autoimmune process and induce tolerance to donor
allografts. Studies have shown that establishment of allogeneic hematopoietic chimerism
by lethal myeloablative conditioning followed by stem cell transplantation allows
restoration of normoglycemia in diabetic NOD/Lt by islet transplantation (101;103). In
the present study, I document that a protocol consisting of a sub-lethal conditioning
regimen can also induce allogeneic hematopoietic chimerism in diabetic mice and permit
them to permanently accept pancreatic islet allografts,
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Stem Cell Transplantation for Tolerance Induction
History
In 1945 , Owen observed that a natural hematopoietic chimeric state, in which two
distinct types of eryhrocytes coexisted, could be generated in fraternal freemarin cattle
twins that shared a common placenta (104). Subsequently, Medawar demonstrated
transplantation tolerance between the chimeric fraternal twins by transplanting skin grafts
from each other (105;106). In their landmark study, Bilingham, Brent, and Medawar
were the first to actively induce allogeneic tolerance through the injection of tissue
suspension containing bone marow cells into embryos or neonatal mice (107)
demonstrating for the first time neonatal tolerance. These studies represent the
foundation upon which most of the subsequent research on tolerance induction by stem
cell transplantation is based. The prevalent scientific explanation was that the neonatal
immune system was not physiologically mature and was immunologically incompetent.
Thus, the donor cells were not rejected and produced an environment conducive to the
development of donor-specific tolerance.
Concept of Tolerance Induction through Hematopoietic Chimerism
Hematopoietic stem cells are single cells that are clonal precursors of more stem
cells of the same type as well as being able to differentiate into progeny capable of
regenerating adult tissues (108). The capacity of hematopoietic stem cells to induce
transplantation tolerance results largely from their ability to induce intrathymic clonal
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deletion of thymocytes with T cell receptors that recognize antigens expressed on the
donor cells (30; 109). The fudamental concept underlying this process is to replicate
nature s major strategy for "self' tolerance as described above. A depiction of this is
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shown schematically in Figure 1.
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Figure 1. Hematopoietic Chimerism and Central Tolerance Induction,
Briefly, once the donor bone marow is injected into the host the hematopoietic
stem cells contained in the inoculum must surive and not be rejected by the host. Once
the stem cells overcome this obstacle and engraft, they give rise to cells of all
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hematopoietic lineages durng the lifetime of the host. These progenitors include antigen
presenting cells (APC) expressing donor antigens that migrate and seed the thymus,
Antigens expressed on cells of hematopoietic origin within the thymus are the most
effective mediators of negative selection (30; 11 0). So , in addition to the deletion of self-
reactive T cells in the thymus , donor-reactive T cells are also negatively selected due to
the presence of the donor APCs. Additionally, the newly developing T cell repertoire in
the chimeric host can also contain immunoregulatory cells that help to maintain
allogeneic tolerance. Once a state of hematopoietic chimerism is successfully
accomplished a robust form of central, and perhaps also peripheral, tolerance is achieved.
Problems to Overcome for Stem Cell Transplantation
The landmark experiments demonstrating that hematopoietic stem cells can
induce tolerance in immunologically immature animals were performed more than 50
years ago, The challenge to this day has been to achieve a similar outcome in
immunologically mature adults. Despite its potent and reliable ability to induce
intrathymic tolerance, hematopoietic stem cell transplantation has not yet been applied to
the induction of tolerance in man mainly due to the "conditioning" required of the host.
Since the donor bone marow cells would be seen as foreign by the recipient' s immune
system, any circulating mature donor-reactive T cells must be eliminated or inactivated to
allow for the surival of the stem cells. The simplest and most widely-used approach to
overcome the immunologic obstacle has been to pre-treat recipients with lethal whole
body irradiation prior to bone marrow transplantation (39; 111), This process would
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eliminate almost all immune lymphocytes, including the donor-reactive T cells, and
produce a "clean" environment for the engraftment of donor stem cells. The treatment
would also be totally myeloablative in that almost all of the host hematopoietic stem cells
would be destroyed or damaged. Implementation of this procedure in animal models to
induce allogeneic chimerism and transplantation tolerance has been very successful
(39; 112). However, widespread utilization of this approach in humans is not feasible
because the lethal radiation would be unduly toxic in individuals who do not have
malignant diseases and who do not need stem cell transplantation for surival.
Another generally used procedure to prevent the rejection of donor hematopoietic
stem cells has been the use of immunosuppressive drgs or nonspecific T cell elimination
(113- 116). The rationale underlying behind both methods is similar in that most tissues
in the host would not be affected, but this procedure would eliminate the immune cells
that mediate the rejection of the donor stem cells, However, the suppression of the
immune system and use of toxic drgs creates major side effects detrmental to the
recipient.
Once hematopoietic chimerism has been achieved, another major complication
arses in the form of graft-vs. host disease (GVHD), especially with the increased clinical
use of grafts from mismatched and unelated donors. GVHD occurs as a result of donor
lymphocytes, present in the transplanted bone marrow, recognizing and attacking host
antigens as foreign. Consequently, the effector phase of the disease involves tissue
damage by cytotoxic T cells (CTL) and natural killer (N) cells (117), Clinically
relevant cases of GVHD occur in 20-50% of patients who receive stem cells from HLA-
identical sibling donors and in 50-80% of those receive who receive stem cells from
HLA-mismatched siblings or from HLA-identical unrelated donors (118). Billngham in
1966 described the essential factors necessary for the development of GVHD: 1) the
graft must contain immunologically competent lymphocytes; 2) the host must express
transplantation antigens that are not present in the donor and that can lead to the
stimulation of donor lymphocytes; and 3) the recipient has to be incapable of
immunologically destroying the graft (119). GVHD is reduced significantly by non-
specifically deleting donor T cells in the inoculum prior to transplantation, but this
procedure leads to a higher incidence of graft failure. A explanation for this phenomenon
may be due to the existence of "facilitating" CD8+ T cells residing in the donor inoculum
that aid in stem cell engraftment (120;121). Deletion of such cells may hinder the
induction of allogeneic chimerism. In vivo blockade of CD40-CD154 interaction using
anti-CDl54 mAb has also been shown to prevent GVHD by blocking the induction of
CD4 help and aborting CD8 alloresponsiveness (122-124). Furher discussion on
blockade of the CD40-CD 154 pathway wil be presented in the next section.
The major obstacles in inducing allogeneic tolerance through stem cell
transplantation have been the conditioning regime necessary to prevent the rejection of
the donor stem cells and the occurence of GVHD once engraftment of the stem cells
have taken place, Recent advances in the transplantation field have shown that these
obstacles can be overcome by the use of reagents designed to stop T cell activation
through co stimulatory blockade.
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Co-stimulatory Blockade and Tolerance Induction
T Cell Activation
The "two-signal" concept of T cell activation proposes that optimal activation of
antigen-specific T cells requires interaction of the TCR with a peptide-MHC complex
expressed on an APC (signal 1), along with an additional co stimulatory signal (signal 2)
(125), Antigen recognition alone, in the absence of signal 2 , has been shown to induce a
state of anergy by shutting down IL-2 production and down-regulating TCR expression
(23;53). A number of molecules with costimulatory fuctions have been identified, but
only a few have been shown to be essential for full T cell activation. Optimal T cell
activation of naIve T cells appears to involve three receptor-ligand interactions (23). 
depiction of this process is shown in Figue 2a. The first interaction is the binding of the
TCR with the peptide-MHC complex (signal 1). The second is binding ofCD154 on T
cells to CD40 on APCs (co-activation). The third interaction is binding of CD80/CD86
(B7, I/B7.2) on the APC to CD28 on the T cell (signal 2 / costimulation). These three
steps lead to the full activation of antigen-specific T cells, A number of strategies for
inducing transplantation tolerance have been developed that involve blocking one or
more of these interactions.
The B7. 1/2-CD28/CTLA4 interaction is the best characterized of the T-cell co-
stimulatory pathways and is crucial for T-cell activation. CD28 is constitutively
expressed on T cells whereas the B7molecules on APCs must be induced by activation of
theAPC (126). The binding of CD28 on T cells to its ligands B7. 1 and B7.2 has been
shown to enhance T
cell proliferation and
IL- production
(127). The absence of
the CD28-B7. 1/2
interaction after TCR
stimulation has been
shown to prevent T
cell activation and
induce anergy
(53; 128). Cytotoxic T
lymphocyte antigen-
(CTLA-4) expressed
on T cells is a second
receptor for B7, 1/2.
Unlike
constitutive
expression of CD28
Activated
APC
the
APC
Allo-Tolerant
Recipient
T Cell
No induction of CDBO/B6 or
pro-inflammatory cytokines
Figure 2. Allo- Tolerance Induction.
CTLA-4 is not expressed on the cell surface for 48-72 hours after T cell activation,
CTLA-4 binds to B7, 1/2 with 10- to 100-fold greater affinity than CD28 (129;130).
CTLA-4 is thought to down-regulate activated T cells by inducing anergy, promoting the
production of inhibitory cytokines, regulating the TCR signaling threshold, and by
affecting cell-cycle progression (131). Its primar role in T cell activation is complex
and remains to be fully understood.
A second important costimulatory signaling pathway is the interaction between
CD40 and its ligand CD154 (CD40L). Antigen-specific stimulation of the TCR (signal
1) induces the rapid upregulation of CD 154 on the surface of the T cell, The subsequent
interaction of CD 154 with its receptor CD40 activates the APC on which the receptor is
expressed. The activation of the APC then induces the upregulation of B7 . 112 expression
on its surface. The interaction ofB7. 1I2 costimulatory molecules with CD28 on T cells
constitutes signal 2 required for T cell activation (23). CD40 is a member of the tumor
necrosis factor (TNF) receptor family that is constitutively expressed on a wide variety of
cells, including dendrtic cells, B cells , macrophages, and endothelial cells (61). CD154
is a member of the TNF cytokine superfamily and is expressed mainly by activated CD4
T cells, but can be found on some CD8+ T cells , mast cells , basophils , NK cells , and B
cells (61). Preventing CD40-CD154 interaction has been shown to block primary and
secondary immune responses to T cell dependent antigens, immunoglobulin class
switching, germinal center formation, and maturation of B cell memory (132;133).
Recent protocols have been developed that block the interaction of CD40 with its ligand
CD154 to induce transplantation tolerance; this approach is termed "co stimulation
blockade.
Peripheral Transplantation Tolerance Induced by Costimulatory Blockade
The use of monoclonal antibodies against CD 154 to block CD40-CD 154
interaction has demonstrated marginal success for inducing allograft survival as a
monotherapy (134). In contrast, the combination of anti-CDl54 mAb plus a donor-
specific transfusion (DST) in the form of donor spleen cells has led to very promising
allograft surival outcomes, It was hypothesized that the "two-element" protocol would
induce allograft survival by first initiating T-cell activation (signal 1) by the introduction
of the DST and preventing co stimulation (signal 2) by the injection of anti-CDl54 mAb
(135;136), depiction of this process is shown in Figue 2b. The absence of
co stimulation would induce T-cell non-responsiveness to the donor alloantigen in the
graft. This hypothesis has been tested in animal models and leads to indefinite survival
of islet and cardiac allografts (135-137). Evaluation of the protocol using a more
challenging assay of transplantation tolerance showed that murne skin allografts can
survive for a prolonged period of time ( 50 days) in euthymic mice, and indefinitely in
thymectomized hosts (134;138). These results suggested that costimulatory blockade by
anti-CDl54 mAb in combination with DST effectively induces a state of peripheral
transplantation tolerance, but does not induce central tolerance. Newly developing
thymic emigrants were able to repopulate the periphery and over time, mediate the
rejection of the donor grafts (139), Mechanistically, transplantation tolerance to skin
allografts in mice using DST plus anti-CDl54 mAb has been shown to be dependent on
IFN-y, CTLA4 , regulatory CD4+ T cells, and the disappearance of alloreactive CD8+ T
cel!s from the circulation (138- 140).
Co-stimulatory Blockade and Allogeneic Chimerism
Non-myeloablative Chimerism Protocols
The need for exhaustive T cell depletion and severe myelosuppressive
conditioning of the host with lethal irradiation or cytotoxic drg treatment for stem cell
transplantation is not feasible for non-fatal , non-malignant diseases. As described next
the use of co stimulatory blocking reagents such as anti-CD 154 mAb as par of the stem
cell transplantation protocol has allowed the induction of allogeneic chimerism to occur
in the absence of these potentially toxic treatments.
Wekerle et aI, showed that allogeneic chimerism and transplantation tolerance
could be induced using co stimulatory blockade (anti-CDI54 mAb and CTLA4-Ig) plus
sub-lethal doses of radiation (141), They demonstrated a thymus-independent deletion of
donor-reactive host peripheral CD4+ cells based on the disappearance of T cells
expressing certain V regions of the p chain in their TCR that specifically recognze
certain superantigens presented by donor MHC. The group furher showed that newly
developing thymocytes bearng these Vp subunits that recognize superantigens are
specifically deleted in the thymus after donor stem cell engraftment.
Although reduced, this protocol stil required some myeloablative conditioning.
The next goal was to develop protocols that would completely eliminate the requirement
for irradiation for stem cell transplantation. Several reports have described approaches
for the successful induction of allogeneic hematopoietic chimerism without any
cytoreductive host treatment (142;143), However, they require supraphysiological doses
of donor bone marow cells. One protocol required 2 x 10 unseparated bone marow
cells with anti-CDl54 mAb and CTLA4-Ig (142), whereas a second protocol required
almost the same dosage at 2 x 10 cells / injection for 8 injections spanning across 3
months (143). These protocols are by far the least toxic treatments described that
successfully induce allogeneic stem cell engraftment, but the quantity of bone marow
cells needed is unlikely to permit extension of these protocols to the clinic.
This thesis describes the use of costimulatory blockade to induce allogeneic
hematopoietic chimerism in autoimmune diabetic NODILt mice and permanently restore
normoglycemia by pancreatic islet transplantation. This thesis also introduces a
chimerism protocol amenable for clinical use by incorporating peripheral transplantation
tolerance induced by administration of DST plus anti-CDl54 mAb to a stem cell
transplantation protocol. Mechanisms important in the induction and maintenance of
allogeneic hematopoietic chimerism are also investigated.
CHAPTER II
MATERIALS AND METHODS
Animals
C57BL/6 (H2
), 
BALB/c (H2
), 
CBA/JCR (H2 and B 1 O, BR (H2 mice were
obtained from the National Cancer Institute, Frederick, MD. NOD/Lt (H2 mice were
obtained from The Jackson Laboratory (Bar Harbor, ME), To investigate the fate of
specific alloreactive T cells , we established in our anmal colony the KB5 TCR transgenic
mouse, which has specificity to native H2 alloantigen (144;145). This TCR transgenic
mouse was the generous gift of Dr. John Iacomini (Harard Medical School, Boston
MA) who obtained it from the original developer, Dr. Andrew Mellor (Medical College
of Georgia, Augusta, GA). The TCR transgene is expressed by CD8+ cells in CBA (H2
mice and has specificity for H2- . These transgenic T cells express a TCR that is
recognized by the DES anti-clonotypic mAb.
All animals were certified to be free of Sendai virus, pneumonia virus of mice
murne hepatitis virus, minute virus of mice, ectromelia, LDH elevating virus , GD7 virus
Reo-3 virus, mouse adenovirus lymphocytic choriomeningitis virus, polyoma
Mycoplasma pulmonis and encephalitozoon cuniculi. All animals were housed in
microisolator cages and given ad libitum access to autoclaved food and acidified water.
They were maintained in accordance with the guidelines of the Institutional Animal Care
and Use Committee (IACUC) of the University of Massachusetts Medical School and
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recommendations in the Guide for the Care and Use of Laboratory Animals (Institute of
Laboratory Animal Resources, National Research Council, National Academy of
Sciences, 1996).
Antibodies and Flow Cytometry
FITC-conjugated anti-H2- (clone AF6-88.5), PE-conjugated anti-H2- (clone
36- 5), and PE-conjugated anti-H2- (clone SF1-1.1) mAbs were obtained from
PharMingen (San Diego, CA). MRI hamster anti-mouse CD154 mAb was produced as
ascites in scid mice and purfied using a Protein A Sepharose 4 Fast-flow purfication
colum (Pharacia Biotech) and quantified by optical density (139;146). Antibody
concentration was determined by measurement of optical density and confirmed by
ELISA (139). The concentration of contaminating endotoxin was determined
commercially (Charles River Endosafe, Charleston, SC) and was uniformly 1 0 units/mg
ofmAb (139).
Anti-CD4 (GK1.5), anti-CD8 (2.43) and anti-CD25 (PC61.5.3) antibodies were
obtained from the American Type Culture Collection (Rockville, MD), Antibodies for 
vivo depletion were produced as ascites in scid mice and purified using a Protein G PLUS
purfication colum (Oncogene Research Products, Boston, MA), To in vivo deplete
CD4+ and CD8+ cells, mice were injected intraperitoneally with 0.5 mg of mAb on three
consecutive days. To in vivo deplete CD25+ cells, mice were injected once
intraperitoneally with 0.25 mg of mAb, A hybridoma cell line secreting hamster anti-
mouse CTLA4 mAb (clone 9HI0) was the gift of Dr. James Allson (University of
California, Berkeley, CA). Anti-CTLA4 mAb was grown as ascites, purfied using
Protein A purification colum (Oncogene Research Products, Boston, MA), and injected
intraperitoneallyat a dose of 0.075 mg per mouse daily on 3 consecutive days.
Flow micro fluorometry was performed as described (139;147). Briefly, 1 x 10
viable cells were reacted with the appropriate antibody for 20 min at 4 C. In experiments
using the KB5 synchimeras, cells were reacted with the DES anti-clonotypic mAb for 20
min. at 4 C. Cells were then washed and reacted with FITC-conjugated anti-mouse
IgG2a mAb (to visualize the bound DES antibody). Whole blood was processed using
F ACS lysing solution (Becton Dickinson, Sunyvale, CA) in accordance with the
protocol supplied by the manufacturer. Labeled cells were washed, fixed with 1 
paraformaldehyde-PBS , and analyzed using a FACScan
(! 
instrent (Becton Dickinson).
Lymphoid cells were gated according their light-scattering properties, and 30-50 x 10
events were acquired for each analysis.
The relative percentages of host- and donor-origin cells in the varous recipients
of C57BL/6 (H2- ) bone marow were determined by flow micro fluorometry. The
percentage of peripheral blood mononuclear cells (PBMC) in chimeric mice expressing
MHC class I was determined by dual labeling with anti-H2- (donor) and anti-H2- , or
anti-H2-K\ (recipient) antibodies, Because fewer than 100% of hematopoietic cells
express MHC class I antigen, the relative percentage of donor-origin cells (H2- ) in
chimeric recipients was calculated as follows: (%H2- b+ + (%H2- b+ + %H2- + or d+)) X
100, In previous experiments, known mixtures of BALB/c and C57BL/6 peripheral blood
mononuclear cells were analyzed, and it was determined that the lower limit of sensitivity
oft e assay for detecting either donor (H2- ) or host (H2- ) cells was 0,5% (147).
Allogeneic Chimerism Induction Protocol #1: Radiation Anti-CD154mAb +
Bone Marrow
Marow donors were female C57BL/6 mice. Donor femurs and tibias were
flushed with RPMI medium using a syrnge with a 24-gauge needle. Recovered cells
were fitered through sterile nylon mesh (70 /-m, Becton Dickinson, Franklin Lakes, NJ),
counted, and re-suspended in RPMI. Recipients were BALB/c or NOD/Lt mice at least 6
weeks of age. In a preliminary experiment, the doses of radiation that produced 100%
mortality in untreated control BALB/c and NOD/Lt mice were determined to be 7 
(N=5) and lOGy (N=5). Doses of 6 Gy (N=5) and 9 Gy (N=5) or less were uniformly
non-fatal. All NOD/Lt recipients were spontaneously diabetic (plasma glucose
concentration ?250 mg/dl) at the time of bone marrow transplantation.
Before transplantation, recipients were randomized to receive anti-CDl54 mAb
plus radiation or radiation alone. All injections of mAb were given intraperitoneally,
Whole body irradiation was administered using a 
I37Cs source (Gammacell 40, Atomic
Energy of Canada, Ottawa, ON, Canada). All recipients received a single intravenous
injection of 25 x 10 donor bone marrow cells in a volume of 0. 0 ml via the lateral
tail vein within 1-5 hrs of irradiation. The doses and timing of the injections, the doses of
radiation, and the timing of injections of mAb in relation to irradiation varied in different
experiments and are described in detail in Chapter III. Blood samples were obtained
from all bone marrow recipients 4-6 weeks after transplantation for determination of the
percentages of donor and host cells by flow micro fluorometry. Additional blood samples
were obtained periodically as described in Chapter III. The presence of hematopoietic
.. .
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chimerism was defined as the presence of 2:1% donor-origin peripheral blood
mononuclear cells.
Allogeneic Chimerism Induction Protocol #2: Radiation DST Anti-
CD154mAb Bone Marrow
Recipients were BALB/c , CBA/J, BI0. , and NOD/LT mice at least 6 weeks of
age. Before bone marow transplantation, recipients were randomized to receive low-dose
radiation, anti-CDl54 mAb and/or donor-specific transfusion (DST). All injections of
mAb were given intraperitoneally at a dose of 0.5 mg on days -
, -
, 0 and +3 relative to
bone marrow transplantation for a total of 4 doses. In some groups, C57BL/6 splenocytes
(10 ) from female donors were injected intravenously in a volume of 0.5 ml into the
varous recipients. The DST was given 7 days prior to bone marow transplantation.
Whole body irradiation was administered using a 13 Cs source (Gamacell 40
Atomic Energy of Canada, Ottawa, ON, Canada). All recipients received a single
intravenous injection of 25 x 10 donor bone marow cells in a volume of 0. 0 ml via
the lateral tail vein within 1-5 hrs of irradiation. Marow donors were female C57BL/6
mice, Donor femurs and tibias were flushed with RPMI medium using a syrnge with a
24-gauge needle. Recovered cells were fitered through sterile nylon mesh (70 flm
Becton Dickinson, Franlin Lakes , NJ), counted, and re-suspended in RPMI,
Blood samples were obtained from all bone marow recipients 4-6 weeks after
transplantation for determination of the percentages of donor and host cells by flow
micro fluorometry. Additional blood samples were obtained periodically as described in
! ;' /'
Chapter IV. The presence of hematopoietic chimerism was defined as the presence of
1 % donor-origin peripheral blood mononuclear cells.
Allogeneic Chimerism Induction Protocol #3: DST Anti-CD 154mAb Bone
Marrow
Bone marrow recipients were BALB/c CBNJ and BI0,BR mice at least 6 weeks
of age. Additional bone marow recipients were KB5 synchimeric mice (described
below). Except as noted in specific experiments, bone marow recipients were treated
with our standard protocol for peripheral transplantation tolerance induction (138- 140).
Relative to the transplantation of allogeneic bone marow on day 0, mice received a
single intravenous donor-specific transfusion (DST , 1 x 10 spleen cells) on day -7 and
four injections of MRI anti-CDl54 mAb (0. mgldose) on days -
, -
, 0 , and +3 (138-
140). The allograft consisted of 50 x or 100 x 10 donor bone marow cells in a
volume of 0. 0 ml, injected via the lateral tail vein.
Femurs and tibias from bone marow donor mice were flushed with RPMI
medium using a syrnge equipped with a 24-gauge needle, Recovered cells were filtered
through sterile nylon mesh (70 , Becton Dickinson, Franklin Lakes , NJ), counted, and
suspended in RPMI for injection, Recipient and donor marrow combinations are
indicated in each Table,
Blood samples were obtained from all bone marow recipients at the times
indicated after bone marrow transplantation for determination of the percentages of donor
and host cells by flow micro fluorometry. Additional blood samples were obtained
periodically as described in Chapters V and VI. The establishment of hematopoietic
chimerism was defined as the presence of ::1% donor-origin peripheral blood
mononuclear cells.
Generation of KB5 TCR Transgenic Hematopoietic CBA Synchimeras
To examine the fate of both matue and developing alloreactive CD8+ T cells in a
normal microenvironment, we used TCR transgenic hematopoietic chimeras (139)
generated by injecting small numbers of bone marow cells from KB5 transgenic donors
into sub-lethally irradiated syngeneic CBA non-transgenic hosts. We refer to these as
synchimeric" mice (139). In this model system there is continual production of low
levels of tracer transgenic cells in a host's cellular microenvironment that is essentially
unaltered by transgene expression,
Donor marrow was collected from male and female KB5 x CBNJCr/F1 mIce
(H2
). 
Donor femurs and tibias were flushed with RPMI medium using a syrnge with a
24-gauge needle. Recovered cells were fitered through sterile nylon mesh (70 j.m
Becton Dickinson, Franlin Lakes , NJ), counted, and re-suspended in RPMI. Recipients
were male CBNJCr mice 4-7 weeks of age, Recipient mice were treated with 2 Gy whole
body gama irradiation using a 13Cs source (Gammace1l40 , Atomic Energy of Canada
Ottawa, ON, Canada). They were given a single intravenous injection of 0,5 x 10
transgenic bone marow cells in a volume of 0,5 ml via the lateral tail vein, The
transgenic T cells that develop from KB5 bone marow express an anti-H2- specific
TCR that is recognized by the clonotypic mAb DES (144). Previously published data
;;,
(139) and results shown in Chapter VI show the generation of stable synchimeras with 5-
8% circulating DES CD8+ cells in the lymphocyte population of PBMC 8 weeks after
bone marow injection.
Skin Transplantation
Full-thickness skin grafts 1 cm in diameter were obtained from shaved donors
scraped to remove muscle, and grafted without suturing onto prepared sites on the flans
of anesthetized recipients as described (138). Skin grafts were dressed with Vaseline
impregnated gauze and an adhesive bandage for the first week after surgery, Thereafter
skin grafts were assessed 3 times weekly, and rejection was defined as the first day on
which the entire graft surface appeared necrotic (138).
Diagnosis of Diabetes and Pancreatic Islet Cell Transplantation
NOD/Lt mice were monitored twice weekly for the presence of glycosura,
Diabetes in glycosurc mice was diagnosed on the basis of two plasma glucose
concentrations 2:250 mgldl on different days (Glucose Analyzer2 , Beckman
Instrents, Fullerton, CA). Prior to islet transplantation, diabetic NOD/Lt mice were
treated with timed release insulin pellets (1 pellet per animal; Linplant , Linshin Canada
Inc.) implanted subcutaneously. Pellets were removed on the day of islet transplantation,
Pancreatic islets were harested from C57BL/6 donor mice by collagenase
digestion as described (135; 148). Islets (20 per g body weight) were transplanted into the
renal sub-capsular space of diabetic NOD/Lt recipients, which were monitored twice
weekly thereafter for the presence of glycosuria. Graft failure was defined as the presence
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of a plasma glucose concentration 250 mg/dl on two successive days, To confirm graft
function in the case of recipients that were normoglycemic at the conclusion of an
experimental protocol, nephrectomy of the kidney containing the islet graft was
performed and the animal was allowed to recover. The graft was scored as having been
fuctional if hyperglycemia recured ( 250 mg/dl).
Histology
Samples of transplanted skin, host skin, small intestine, large intestine, and liver
were recovered from selected experimental mice, fixed and stored in 10% buffered
formalin solution, then embedded in paraffn and processed for light microscopy.
Kidneys into which islet grafts had been transplanted were processed in the same way.
Sections for routine light microscopy were stained with hematoxylin and eosin, Sections
of islet graft-bearng kidneys were stained immunohistochemically for the presence of
insulin and glucagon as described (149), Portions of islet graft-bearing kidneys were also
snap frozen and processed for immunohistochemistr as described (150). Sections were
reacted with antibodies directed against CD3 , CD4, CD8 , and CDI9. Histological
analyses were performed by a qualified pathologist (BA W) who was unaware of the
treatment status of specimen donors.
Statistical Analysis
Comparsons of three or more means used oneway analyses of varance and the
least significant difference procedure for a posteriori contrasts (151). Comparsons of
two means used unpaired t-tests without assuming equal variance (152). In experiments
":p
in which large variances were observed, groups were compared non-parametrically with
the Man-Whitney U or Krskall-Wallis tests (153). Analysis of contingency tables used
the X statistic or, in the case of 2 x 2 tables, the Fisher exact statistic (153), Average
duration of graft survival is presented as the median survival time (MST). Skin allograft
surival among groups was compared using the method of Kaplan and Meier (154); the
equality of allograft survival distributions for anmals in different treatment groups was
tested using the log rank statistic (155). P values c:O,05 were considered statistically
signficant.
CHAPTER III
ALLOGENEIC CHIMERISM INDUCED BY SUB-LETHAL
RAIATION AND ANTI-CD154 ANTIBODY
Introduction
Stem cell transplantation leading to allogeneic hematopoietic chimerism has been
proposed as a method for both the generation of transplantation tolerance and the
treatment of autoimmune diseases, As stated above, implementation of clinical trials has
in par been impeded by the toxicity of conditioning procedures and by the development
of graft-versus-host disease (GVHD), The theory is that procedures that induce
peripheral tolerance to allogeneic grafts may facilitate in the induction of allogeneic
chimerism. One class of tolerance induction protocols is based on blockade of the CD40-
CD154 T cell co stimulatory pathways using anti-CDl54 mAb. So , the hypothesis is that
blockade of the CD40-CD154 interaction will eliminate the need for lethal myeloablative
preparation to induce chimerism and simultaneously prevent GVHD. I have tried to
develop a clinically relevant hematopoietic chimerism protocol by using anti-CDl54
mAb in conjunction with sub-lethal radiation and fully allogeneic bone marrow cells,
Additionally, I have explored the use of this chimerism protocol as a treatment for type 
diabetes using the NOD/Lt mouse model for autoimmune diabetes.
Results
Blockade of CD40-CD154 Interaction Permits Establishment of C57BL/6
Hematopoietic Chimerism in BALB/c Mice Without Lethal Conditioning
We first established that it is possible to generate hematopoietic chimerism in
BALB/c (H2 mice transplanted with fully allogeneic C57BL/6 (H2 bone marrow
using the combination of sub-lethal irradiation and a brief course ofanti-CDl54 mAb. As
shown in Table 1 , chimerism could be established using as little as 4 Gy of conditioning
radiation and as few as two doses of anti-CDl54 mAb. The percentage of successful
transplantation procedures yielding detectable chimerism using 4 Gy varied as a function
of the dose and frequency of treatment with anti-CDl54 mAb. Treatment with only two
doses of 0.5 mg of mAb was optimal, yielding chimerism in 100% of nine mice in two
independent trials. Chimerism could also be established without blockade of CD154 in
recipients given 5 Gy but not 4 Gy of conditioning radiation.
The data shown in Table 1 were obtained 4-6 weeks after transplantation. All
mice documented to be chimeric at this time point were subsequently reanalyzed at
varying intervals 49 to 338 days after transplantation. Analysis of PBMC demonstrated
that, without exception, they remained chimeric to the same degree as indicated in Table
Mice were ultimately killed at varying intervals 27-48 weeks after transplantation
for histological studies and flow microfluorometrc analyses of spleen, thymus, and bone
marow. In mice that were given 4 Gy or 5 Gy of conditioning radiation and 4 or 14
Table 1: Hematopoietic Chimerism in BALB/c Mice Given Varying Sub-lethal Doses of
Radiation and C57BL/6 Bone Marrow in the Presence or Absence of Anti-CDI54
Anti-CD154 mAb
Radiation Number of
Percentage of Donor
Origin PBMC in(Gy) Number of Injections Dose Chimeric Mice 
(%)
Chimeric Mice
None 0/10 (0%)
25 mg 0/5 (0%)
25 mg 0/5 (0%)
5 mg 0/5 (0%)
None OlIO (0%)
25 mg 2/4 (50%) Both ;:99%
25 mg 4/9 (44%) All ;:99%
5mg 919 (100%) All ;:99%
None 10/10 (100%) All ;:99%
25 mg 4/4 (100%) All ;:99%
25 mg 8/9 (89%) All ;:99%
5 mg 919 (100%) All ;:99%
Legend to Table 1: BALB/c (H2 mice were iradiated, transfused intravenously with 25 x 10
C57BL/6 (H2 bone marrow cells, and injected intraperitoneally with anti-CDl54 mAb as indicated.
The schedule of anti-CDl54 mAb (relative to iradiation and bone marrow transplantation on day 0)
was as follows, Recipients given 2 injections were treated on days 0 and +3 , recipients of 4 injections
on days - , 0, +3 , +7 , and recipients of 14 injections on days - , 0, and twice weekly thereafter. The
percentage of donor origin peripheral blood mononuclear cells (PBMC) was determed by flow
cytometr 4-6 weeks after iradiation and bone marrow transplantation. The presence of chimerism was
defmed as 1 % donor-origin cells.
doses of anti-CDl54 mAb 99% of splenic B cells, CD4+ T cells, and CDS+ T cells
detected were of donor-origin (N=9). In contrast, the percentage of donor-origin
thymocytes in chimeric recipients was generally much smaller, 57 :t 27% (range 17 to
99%, N 9). Bone marrow cells were 99% donor-origin. We also analyzed two
chimeric mice that had received only 5 Gy of conditioning radiation and no anti-CDl54
mAb. In these mice 99% of B cells, CD4+ T cells , and CD8+ T cells were of donor-
" ...' .
origin. The percentages of donor-origin thymocytes in these two mice were :;99% and
J .
60%. Bone marow cells were :;99% donor-origin in both.
The diagnosis of GVHD was made either clinically or histologically. Throughout
the period of observation (up to 338 days) there was no clinical evidence of GVHD in
any chimeric bone marow recipient that had received any dose of radiation plus any of
the anti-CD 154 mAh regimens (N=36, Table 1), This was true in the case of mice that
were not further manipulated (N=22) and mice that were given donor-specific skin
allografts (N=14, described below). The absence of GVHD was confirmed by
histological study of skin, liver, and small and large intestine in a subset of the animals
that were skin graft recipients (N=9). Two of the nine mice showed rare apoptotic bodies
in intestinal cryts, but cryptitis was absent. Similarly, the livers of two of nine mice
showed scattered peripheral lymphocytes, but bile duct inflamation was not evident.
Skin biopsies were unremarkable.
Among the ten chimeric BALB/c recipients that had been given 5 Gy of
conditioning radiation but no anti-CDl54 mAb, seven survived:;10 weeks, The other
three exhibited clinical signs of GVHD before death; these included weight loss, loss of
hair, hunched posture, and eryhematous encrusted ears. The remaining seven anmals
were confirmed still to be chimeric 7-21 weeks after bone marow transplantation and
given skin allografts as described in the next section. Among these, five subsequently
died with clinical evidence of GVHD. Two suriving mice in this group were kiled on
day 112 after skin grafting for flow cytometric and histological analyses. Both were
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documented to have remained chimeric, and neither showed histological evidence of
GVHD.
Donor-specifc Skin Allografts Uniformly Survive in Chimeric Mice that Receive
Anti-CD154 Antibody
We next measured the surival of donor-origin skin allografts on a subset of the
bone-marow transplanted mice presented in Table 1. Selected mice from among those
tested for chimerism 4-6 weeks after bone marrow transplantation were given C57BL/6
skin grafts 3 to 15 weeks later,
Donor-specific (C57BL/6) skin allograft survival on chimeric mice given any of
the anti-CD 154 mAb treatment regimens plus either 4 Gy (N=6) or 5 Gy (N=8) was
signficantly prolonged (MST ::183 d and ::112 d, respectively). Graft survival in these
two groups was statistically similar, and the groups were combined in subsequent
analyses (Figure 3 , Group 1). Median skin allograft survival was statistically significantly
longer on mice that had received both radiation and anti-CDl54 mAb (MST=166 d
N=14 , Figure 3 , Group 1) than on chimeric mice that had received only 5 Gy of radiation
(MST=9 d, N=7, Figue 3 , Group 2). As can be seen in the figure, skin graft survival on
three of the seven chimeric animals that had received radiation alone was prolonged. One
of these three mice had clinical signs of GVHD and died with its graft intact. The other
two were killed for histological study 112 days after skin grafting when one of them
became ill, As noted at the end of the previous section, both of these mice were chimeric
and neither showed histological evidence of GVHD, The skin graft from one animal
showed scattered mononuclear cells around hair follicles and sweat glands, and rare
apoptotic keratinocytes and intradermal mononuclear cells. The other graft was
unremarkable, with no evidence of mononuclear infiltration.
Skin allograft survival on irradiated mice that had failed to become chimeric
1 % donor cells) was uniformly brief regardless of whether or not they had received
anti-CDl54 mAb (Figure 3 , Groups 3 , 4; MST=9 d for both groups),
We next determined if skin allograft survival on chimeric BALB/c recipients of
C57BL/6 bone marow was donor-specific, A subset of mice that were documented to be
chimeric after treatment with both conditioning irradiation (4 or 5 Gy) and anti-CDl54
mAb (2 doses) was selected at random 14- 15 weeks after bone marrow transplantation.
They were given either C57BL/6 (H2 donor-specific) or CBA/JCR (H2\ pary) skin
allografts. As expected, donor-specific (C57BL/6) skin allograft survival on chimeric
mice was signficantly prolonged (MST :;65 d, N=3). In contrast CBA/JCR skin
allografts surived only briefly (MST=15 d, N=4).
Histological analysis of transplanted skin was performed on a subset of 11 mice
with intact grafts that had survived for 64-259 days, These included 9 chimeric recipients
that had received radiation plus anti-CDl54 mAb and 2 that had received radiation alone.
In all instances, there was no evidence of inflamation suggestive of graft rej ection,
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Figure 3. C57BL/6 Skin Allograft Survival in BALB/c Recipients of C57BL/6 Bone
Marrow. Both chimelic and non-chimelic BALB/c mice from among those desclibed in Table 1 were selected
at random and transplanted with a C57BL/6 skin graft 7 to 19 weeks after bone marrow transplantation as
desclibed in Methods. For puroses of analysis , mice were divided into four groups. Mice in Group 1 had received
either 4 or 5 Gy of conditioning radiation plus anti-CDl54 mAb and were chimelic. MST of grafts in this group
was ;,166 days. Mice in Group 2 had received 5 Gy of conditioning radiation but no anti-CD 154 mAb and were
chimeric. MST of grafts in this group was 9 days. Mice in Group 3 had received either 4 or 5 Gy of radiation plus
anti-CDl54 mAb , but were not chimelic. Mice in Group 4 were given 4 Gy of radiation but no anti-CD 1 54 mAb
and were not chimeric. MST of grafts in both Group 3 and Group 4 was 9 days. Graft surival in Group 1 was
significantly longer than in any other group (p OOOI). Censored data e. mice that died or were killed for
histological study or were stil alive at the end of the experiment are indicated by vertical lines.
Blockade of CD40-CD154 Interaction Permits Establishment of C57BL/6
Hematopoietic Chimerism in Sublethally Conditioned NOD/Lt Mice
We next established that it is possible to generate hematopoietic chimerism in
NOD/Lt (H2 mice transplanted with allogeneic C57BL/6 (H2 bone marrow using the
combination of sub- lethal irradiation and a brief course of anti-CDl54 mAb. In this
experiment, all NOD/Lt recipients had developed spontaneous autoimmune diabetes prior
to conditioning and bone marow transplantation. Consistent with a previous report (103),
a preliminary experiment demonstrated that NOD/Lt mice are relatively radioresistant;
the lethal radiation dose was lOGy, We tested for the generation of chimerism in
NOD/Lt mice using 6 to 9 Gy of conditioning radiation.
As shown in Table 2, hematopoietic chimerism in NOD/Lt mice could be
generated using as little as 6 Gy of conditioning radiation provided that the mice were
also treated with anti-CDl54 mAb, As few as two doses of anti-CDl54 mAb were
suffcient. Chimerism could also be established without blockade of CD 154, but required
a minimum of 7 Gy of conditioning radiation.
The percentage of transplantation procedures yielding detectable chimerism in
mice given both radiation and anti-CDl54 mAb varied with the dose and frequency of
treatment with the mAb. As was true in the case of BALB/c recipients of C57BL/6 bone
marrow, treatment with two doses of 0.5 mg of mAb was optimal at each dose of
radiation.
The data shown in Table 2 were obtained 4-6 weeks after transplantation, Mice
initially observed to be chimeric at this time point were subsequently reanalyzed at
varyng intervals 49 to 331 days after transplantation. With the exception of one mouse
they were all documented to have remained chimeric to the same extent as indicated in
Table 2. In the one exceptional mouse, the percentage of donor-origin cells at 4 weeks
was atypically low (24%) and no donor-origin cells could be detected at 7 weeks,
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Table 2: Hematopoietic Chimerism in NOD/Lt Mice Given Varing Sub-Lethal Doses of
Radiation and C57BL/6 Bone Marow in the Presence or Absence of Anti-CDI54
Radiation
Anti-CD154 mAb Percentage of DonorNumber of chimeric
(Gy) Number of Dose mice 
(%)
Origin PBMC in Chimeric
ections Mice
None 0/6 (0%)
25 mg 3/6 (50%) 24% 93% , :?99%
5 mg 8/12 (67%) 95% , 97% , Six :?99%
None 4/4 (100%) All :?99%
0.25 mg 1/3 (33%) All :?99%
5mg 5/6 (83%) All :?99%
None 2/2 (100%) Both :?99%
25 mg 0/2 (0%)
5mg 3/3 (100%) All :?99%
25 mg 6/6 (100%) All :?99%
5mg 3/3 (100%) All :?99%
Legend to Table 2: Spontaneously diabetic NOD/Lt mice (H2 were iradiated, transfused
intravenously with 25 x 10 C57BL/6 (H2 bone marrow cells, and injected intraperitoneally with anti-
CD154 mAb as indicated. The schedule of anti-CD 154 mAb (relative to iradiation and bone marrow
transplantation on day 0) was as follows. Recipients given 2 injections were treated on days 0 and +3
and recipients of 14 injections on days - , and twice weekly thereafter. The percentage of donor
origin peripheral blood mononuclear cells (PBMC) was determed by flow cytometr 4-6 weeks after
iradiation and bone maow transplantation. The presence of chimerism was defined as 1 % donor-
origin cells,
Mice were ultimately killed at varng intervals 16-42 weeks after transplantation
for histological studies and flow microfluorometric analyses of spleen, thymus, and bone
marow. Except for the one anmal described above 99% of splenic B cells, CD4+ T
cells, and CD8+ T cells detected were of donor-origin, In the one exceptional case, no
donor-origin cells could be detected in blood, spleen, bone marow, or thymus 20 weeks
after transplantation. As was also tre of the BALB/c recipients of C57BL/6 bone
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marow (Table 1), the average percentage of donor-origin thymocytes in chimeric
NOD/Lt recipients (Table 2) was lower, 61 :! 37% (range 25-99%, N=5),
The diagnosis of GVHD in these mice was made either clinically or
histologically, Throughout the period of observation (up to 331 days) there was no
clinical evidence of GVHD in any chimeric NOD/Lt bone marow recipient that had
received any dose of radiation plus any of the anti-CDl54 mAb regimens (N=29 , Table
2), This was true in the case of mice that were not fuher manipulated (N=10) and mice
that were given donor-specific allografts (N=19, described below). The absence of
GVHD was confirmed by histological study of skin, liver, and small and large intestine in
a subset ofthe animals that were allograft recipients (N=II). Five of eleven mice showed
scattered peri-portal lymphocytes. The skin and intestine were unremarkable.
Among the six chimeric NOD/Lt recipients that had been given 7 or 8 Gy of
conditioning radiation but no anti-CDl54 mAb , three were found dead within 6 weeks of
bone marow transplantation. These mice died before they could receive islet grafts, and
the causes of death are not known. The three remaining mice were given islet grafts as
described in the next section. Two mice survived 23 weeks after bone marow
transplantation without clinical evidence of GVHD. The third died with clinical evidence
of GVHD shortly after islet grafting,
Donor-specifc Islet Allografts Uniformly Survive in Chimeric NOD/Lt Mice and
Reverse Autoimmune Disease
We next measured the surival of donor-origin islet allografts on a subset of the
bone-marrow transplanted NOD/Lt mice presented in Table 2. Selected mice from among
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those tested for chimerism 4-6 weeks after bone marrow transplantation were given
C57BL/6 islet allografts 1 week later. These mice had spontaneously developed
autoimmune diabetes before bone marrow transplantation. They were treated with slow-
release insulin pellets until the day of islet transplantation , at which time the pellets were
removed.
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Figure 4. C57BV6 Islet Allograft Survival in Diabetic NOD/Lt Recipients of C57BL/6
Bone Marrow. Both chimeric and non-chimeric NOD/Lt mice from among those described in Table
2 were selected at random and transplanted with a C57BL/6 islet graft 5-7 weeks after bone marrow
transplantation as described in Methods. All mice were diabetic at the time of both bone marrow and
islet transplantation; their diabetes was treated with sustained-release insulin pellets until islet
transplantation, at which time the pellets were removed. For purposes of analysis , mice were divided
into three groups. Mice in Group 1 had received 6 to 9 Gy of conditioning radiation plus anti-CD 154
mAb and were chimeric. Median survival of islet grafts in this group was ::120 days. Mice in Group 2
had received 6 to 8 Gy of conditioning radiation and anti-CD 154 mAb and were non-chimeric. Mice in
Group 3 had received 6 Gy of radiation but no anti-CD 154 mAb and were non-chimeric. MST of graft
in Groups 2 and 3 was 3 days. Graft surival in Group 1 was significantly longer than in the other
groups (p.:O.OOOl). Graft survival in Groups 2 and 3 was statistically similar. Censored data e. mice
that died or were nephrectomized at the end of the experiment, are indicted by vertcal lines.
Islet allograft survival in chimeric diabetic NOD/Lt mice given any of the anti-
J -
CD154 mAb treatment regimens plus any dose of conditioning radiation was
significantly prolonged. Through the end of the experiment, none of these 19 islet
recipients rejected its graft (MST ::120 d, Figure 4, Group I). One mouse died
unexpectedly 12 days after islet transplantation, but was normoglycemic 2 days before
death. The mouse did not exhibit signs of GVHD , and the cause of death is not known,
To confirm graft function 11 of the 18 long-term islet allograft recipients underwent
unilateral nephrectomy of the islet graft-bearng kidney 75-276 d after islet
transplantation. Hyperglycemia recurred in all nephrectomized mice, confirming the
prolonged survival and function of the transplanted islets.
As noted at the end of the previous section, only three NOD/Lt mice that had
become chimeric after irradiation alone surived long enough to receive islet grafts. Two
received NOD-scid islet grafts; one received a C57BL/6 islet graft. The NOD-scid graft
recipients died 40 and 185 days after transplantation. Both were normoglycemic
immediately before death, but the mouse that died on day 40 showed evidence of GVHD,
The single recipient of C57BL/6 islets remained normoglycemic and clinically well until
the conclusion of the experiment 260 days after islet grafting,
Islet allograft surival in irradiated mice that had failed to become chimeric (0:1 %
donor cells) was uniformly brief. This was true both for recipients that had received anti-
CD154 mAb (N=9 , MST=3 d, Figure 4 , Group 2) and for those that had not (N=4 , MST=
3 d, Figure 4, Group 3),
Histological analysis of transplanted islets was performed on the 11 nephrectomy
specimens described above (Figue 5), In some cases, light microscopy revealed a very
sparse mononuclear cell infiltrate in the renal capsule or adjacent to the islet graft, but no
mononuclear cell infitrates were observed the grafts themselves.
Imunohistochemical analyses using antibodies specific for CD3 , CD4, CD8 , and CD19
confirmed that few or no lymphoid cells were present in the transplanted tissue,
Consistent with the observation that hyperglycemia recurred after nephrectomy,
immunohistochemical staining demonstrated that insulin was present in each specimen.
Imunoreactive glucagon was also detectable in each specimen.
Figure 5. Histology of a Representative C57BL/6 Islet Allograft from a Chimeric NOD/Lt
Recipient. Shown are histological sections of C57BL/6 islet tissue that had been transplanted into the
renal sub-capsular space of a chimeric NOD/Lt mouse. The NOD/Lt recipient had developed
spontaneous autoimmune diabetes and had been treated with radiation and anti-CDl54 mAb and
C57BL/6 bone marrow 4 weeks before islet transplantation (see Methods). This recipient was
normoglyeemie for 124 days after transplantation and became hyperglycemic immediately after
recovery of the kidney bearing the islet tissue shown here. A: Hematoxylin and eosin stained section
showing nOfflal appearing islet tissue. An inflammatory infiltrate (x 150) was not evident. B: A frozen
section stained immunohistochemically for the presence of the CD3+ lymphocytes. There is no
appreciable CD3 + T cell infiltrate. (x 150) C and D: Sections stained immunohistochemically for the
presence of insulin and glucagon, respectively. Abundant hormone-containing cells are visible (x 150).
Skin Allograft Tolerance is Donor-specifc in Allogeneic NOD/Lt Hematopoietic
Chimeras bearing Functional Donor-specifc Islet Allografts
We next determined whether the state of transplantation tolerance in chimeric
NOD/Lt recipients of C57BL/6 bone marrow was donor-specific , as was the case for the
chimeric BALB/c recipients described above. A subset of NOD/Lt mice that had been
treated with conditioning radiation plus anti-CDl54 mAb and were normoglycemic 100
days after transplantation of C57BL/6 islets were selected at random. They were given
either a C57BL/6 (H2 donor-specific) or a CBNJCR (H2 party) skin allograft.
Survival ofC57BL/6 skin allografts was significantly prolonged (MST 128 d, N=3). In
contrast CBNJCR skin allografts surived only briefly (MST=15 d, N=3 , Table 3).
None of the islet allografts failed in either group durng the period of observation, and
recurence of hyperglycemia after unilateral nephrectomy was observed in all mice.
Histological analysis of the donor-specific C57BL/6 skin grafts obtained at the
conclusion of the experiment showed no evidence of inflamation suggestive of graft
rejection.
Table 3: Skin Allograft Survival on Chimeric NOD/Lt Mice Bearing Donor-Specific Islet
Allografts
Bone Marrow
Donor
Islet Allograft
Donor
Skin Allograft
Donor
Skin Allograft Survival
(days)
).26 , ).128 , ).128
, 15
C57BL/6
C57BL/6
C57BL/6
C57BL/6
C57BL/6
CBAlJCr
Legend to Table 3: Chimeric NOD/Lt mice bearing C57BL/6 islet allografts were selected at
random ftom among those presented in Figue 4 (Group 1). They were given either a C57BL/6 (H2
donor-specific) or a CBA/JCr (H2 part) skin allograft as described in Methods. None of the islet
allografts failed in either group durg the period of observation.
Summary
I describe a tolerance-based stem cell transplantation protocol that combines sub-
lethal irradiation with transient blockade of the CD40-CD 154 co stimulatory pathway
using an anti-CDl54 antibody. With this protocol , I established hematopoietic chimerism
in BALB/c mice transplanted with fully allogeneic C57BL/6 bone marow. The
percentage of donor-origin mononuclear cells in recipients was 99%. In addition, all
chimeric mice treated with anti-CDl54 antibody remained free of graft vs. host disease
(GVHD) and accepted donor-origin but not third pary skin allografts. It was similarly
possible to create allogeneic hematopoietic chimerism in NOD/Lt mice with spontaneous
autoimmune diabetes, Pancreatic islet allografts transplanted into chimeric NOD/Lt mice
were resistant not only to allorejection but also to recurence of autoimmunity. I conclude
that it is possible to establish robust allogeneic hematopoietic chimerism in sub-lethally
irradiated mice without subsequent GVHD by blocking the CD40-CD154 costimulatory
pathway using as few as two injections of anti-CDl54 antibody. I also conclude that
chimerism created in this way generates donor-specific allograft tolerance and reverses
the predisposition to recurrent autoimmune diabetes in NOD/Lt mice, enabling them to
accept curative islet allografts.
CHAPTER IV
DST + ANTI-CD154 ANTIBODY LOWERS RAIATION
REQUIREMENT FOR ALLOGENEIC CHIMERISM INDUCTION
IN NORML MICE
Introduction
The major objective in stem cell transplantation is the survival of the injected
allogeneic hematopoietic donor cells so that they can engraft and establish a chimeric
state in the host. Earlier attempts to prolong the surival of the donor stem cells involved
total myeloablative regimes and immunosuppressive drgs. Recently, I have developed
an allogeneic chimerism induction protocol that requires only sub-lethal radiation by
using anti-CDl54 mAb. Even though the use of lethal radiation was eliminated, a high
dose was stil required to establish hematopoietic chimerism. In an effort to lower the
radiation requirement, I adapted the protocol involved in peripheral tolerance induction
that has been used in our lab to the induction of hematopoietic stem cell engraftment.
Our lab has published that DST plus anti-CDl54 mAb greatly prolongs the survival of
allogeneic grafts and deletes alloreactive CD8+ T cells. I hypothesized that DST plus
anti-CDl54 mAb would also prolong the survival of allogeneic stem cells facilitating
their ability to engraft in the host. I theorized that the deletion of the alloreactive CD8+ T
cells before bone marow introduction would lower the radiation requirements.
Results
Large Doses of Bone Marrow Cells with Anti-CD154 mAb Does Not Lower
Radiation Dose Requirements
In an effort to determine if increasing the amount of bone marrow cells injected
into the host would decrease the dose of radiation required for chimerism induction, I
vared the radiation dose and bone marow cell numbers. As shown in Table 4, one
group of BALB/c mice was given 4 Gy of radiation, 25 x bone marow cells from
C57BL/6 donors, and a short course of anti-CDl54 mAb, As expected, all of the
BALB/c mice in this group became chimeric with 90,8% of their PBMC being of donor-
origin. Increasing their bone marow dose to almost 10 times the standard dose and
decreasing their irradiation to 2, 1 or 0 Gy did not induce chimerism induction in any of
the BALB/c mice (Table 4). In an effort to see if extending the injection of bone marow
might facilitate chimerism induction, BALB/c mice were given 40 x 10 C57BL/6 bone
marow cells each day for five consecutive days for a total of 200 x 10 donor bone
marow cells in combination with anti-CDl54 mAb treatment. None of the mice turned
chimeric using this protocol.
Table 4: Mega-dose Bone Marrow Transplantation with Anti-CDI54 mAb in BALB/c Mice
using C57BL/6 Donors
Percentage of
Radiation Bone Marrow Anti-CD154 Number of Donor-Origin
(Gy) Dose mAb Chimeric Mice (%) PBMCs in
Chimeric Mice
25x 10 5/5 90.
200x 10 0/3
200xl0 0/3
200xl0 0/8
5 X 40xl0 0/5
Legend to Table 4: BALB/c (H2 mice were randomly grouped to receive 0, 1 2 or 4 Gy of
iradiation. The mice were then transfused intravenously with C57BL/6 (H2 bone marrow cells at 3
different dose regimens: 25x10 cells on Day 0; 200x106 cells on Day 0; and 40x10 cells/day on Days
, 1 , 3 and 4. The hosts were also injected intraperitoneally with 2 injections of anti-CD 154 mAb at
5 mg per injection on days.O and +3 (relative to bone marrow transplantation on day 0). PBMCs from
the hosts were analyzed 4-6 weeks after bone marrow transplantation.
DST in Conjunction with Anti-CD154 mAb Lowers the Radiation Requirement for
Allogeneic Chimerism in Normal Inbred Mice
I hypothesized that the procedure to induce peripheral transplantation tolerance
could help induce allogeneic hematopoietic chimerism with less radiation then previously
required using anti-CDl54 mAb plus bone marow cells. BALB/c mice were given
donor-specific transfusion (DST) consisting of 10 x spleen cells plus anti-CDl54
mAb , irradiated at varying doses, and injected with 25 x 10 C57BL/6 bone marrow cells.
As shown in Table 5 , 4 Gy of radiation, which is sufficient for BALB/c mice to become
chimeric by injection of bone marrow and anti-CDl54 mAb (Table 4), was also suffcient
to induce allogeneic chimerism in all of the mice treated with DST, anti-CDl54 mAb
and bone marow. Most of the PBMC analyzed (99.7%) was of donor-origin, Lowering
the radiation down to 2 and 1 Gy resulted in 89% (8/9) of the BALB/c mice becoming
chimeric with 28.4% and 21.0% donor-origin cells, respectively, Unexpectedly, 3 Gyof
radiation did not lead to any chimeric mice in the 3 BALB/c mice treated. More animals
need to be tested to determine if the result is due to statistical insufficiency in light of the
fact that almost all of the mice treated with 2 or 4 Gy of radiation became chimeric, An
additional experiment to determine the effect of increasing the bone marrow cell dose to
50 X 10 with 1 Gy, DST and anti-CDl54 mAb produced chimeric mice in 100% (5/5) of
the BALB/c and increased the percentage of donor-origin cells in the PBMC to 37%,
I next determined if the protocol could induce allogeneic chimerism in other
Table 5: DST plus Anti-CDI54 mAb and Bone Marrow Regime Lowers Radiation
Requirement for Hematopoietic Chimerism Induction in BALB/c Mice Using C57BL/6
Donors
Bone Bone Number of Percentage ofRadiation DST donor Anti-CD154 Marrow Marrow Chimeric Donor-Origin(Gy) mAb Donor Dose Mice (%) PBMCs inChimeric Mice
C57BL/6 C57BL/6 25xl0 313 99.
C57BL/6 C57BL/6 25x10 013
C57BL/6 C57BL/6 25xl0 819 28.4%
C57BL/6 C57BL/6 25xl0 819 21.0%
C57BL/6 C57BL/6 50xl0 515 37.
Legend to Table 5: BALB/c (H2 mice were given DST by receiving 10 x 10 splenocytes
trom C57BL/6 (H2 donors on day -7 intravenously. They were injected intraperitoneally with 4
injections of anti-CD 154 mAb at 0.5 mg per injection on days -
, -
, 0, +3 (relative to bone marrow
transplantation on day 0). The hosts were iradiated with 1 , 2, 3 or 4 Gy on Day O. They were then
transfused intravenously with 25 x 10 or 50 x 10 C57BL/6 (H2 bone marrow cells. PBMCs trom
the hosts were analyzed 6-7 weeks after bone marrow transplantation.
strains of mice. BI0.BR mice were treated with C57BL/6 DST plus anti-CDl54 mAb.
The mice were separated into groups based on the dose of irradiation and the number of
C57BL/6 bone marrow cells injected. As shown in Table 6, 100% ofBI0,BR mice given
25 x 10 bone marrow cells and 4 or 3 Gy of radiation became chimeric with 78.6% and
61.5% donor-origin cells in their PBMC, respectively. In an effort to increase the
likelihood of obtaining chimeric mice with even lower doses of radiation, the bone
marrow dosage for the next two groups was increased to 50 x 10 cells. As seen in Table
2 and 1 Gy of radiation also led to chimerism in all ofthe BlO.BR hosts.
Table 6: DST plus Anti-CDI54 mAb and Bone Marrow Regime Lowers Radiation
Requirement for Hematopoietic Chimerism Induction in BI0.BR Mice Using C57BL/6
Donors
Anti- Bone Bone Number of Percentage ofRadiation DST donor CDl54 Marrow Marrow Chimeric Donor-Origin(Gy)
mAb Donor Dose Mice (%) PBMCs inChimeric Mice
C57BL/6 C57BL/6 25x10 515 78,
C57BL/6 C57BL/6 25xl0 515 61.5%
C57BL/6 C57BL/6 -5 Ox 10 515 74.3%
C57BL/6 C57BL/6 50x10 515 57,
Legend to Table 6: BlO.BR (Hi') mice were given DST by receiving 10 x 10 splenocytes
from C57BL/6 (H2 donors on day -7 intravenously. They were injected intraperitoneally with 4
injections of anti-CD 154 rnb at 0.5 mg per injection on days -
, -
, 0, +3 (relative to bone marrow
transplantation on day 0), The hosts were iradiated with 1 , 2 , 3 or 4 Gy on Day O. They were then
transfused intravenously with 25 x 10 or 50 x 10 C57BL/6 (H2 bone marrow cells. PBMCs from
the hosts were analyzed 5-6 weeks after bone marrow transplantation,
A third strain of mice was tested using the protocol with low dose of irradiation to
confirm that the results were not strain biased, CBA/J mice were given DST plus anti-
CD154 mAb and 50 x 10 C57BL/6 bone marow cells along with 2 or 1 Gy of radiation.
100% of the mice in both groups became chimeric with both expressing 30% donor-
origin cells in their PBMC (Table 7).
Table 7: DST plus Anti-CDI54 mAb and Bone Marrow Regime Facilitates Induction of
Hematopoietic Chimerism in CBA/J Mice Using C57BL/6 Donors with Low-dose Iradiation
Percentage of
Radiation Anti- Bone Bone Number of Donor-Origin
(Gy) DST donor CD154 Marrow Marrow Chimeric PBMCs in
mAb Donor Dose Mice (%) Chimeric
Mice
C57BL/6 C57BL/6 50x10 515 33.
C57BL/6 C57BL/6 50xl0 919 35.
Legend to Table 7: CBAlJ (Hi) mice were given DST by receiving 10 x 10 splenocytes from
C57BL/6 (H2 donors on day -7 intravenously. They were injected intraperitoneally with 4 injections
of anti-CDl54 mAb at O,5mg per injection on days -
, -
, 0, +3 (relative to bone marrow
transplantation on day 0). The hosts were iradiated with 1 or 2 Gy on Day O. They were then
transfused intravenously with 50 x 10 C57BL/6 (H2 bone maow cells. PBMCs from the hosts were
analyzed 5-6 weeks after bone marrow transplantation.
DST plus Anti-CD154 mAb Does Not Permit Establishment of Allogeneic
Chimerism in NOD/Lt with less than 6Gy of Radiation Pretreatment
The promising results obtained in normal inbred strain mice using DST and anti-
CD154 mAb led to our testing the protocol in NOD mice. As shown in Table 8 , the
protocol consisting of allogeneic bone marow cells and anti-CDl54 mAb yielded
chimeric mice only when at least 6 Gy of irradiation was used; 5 Gy did not produce any
. chimeras. The addition of DST into the protocol also yielded chimeras in 60% of the
. ' : .-"y; - ' '
mice irradiated with 6 Gy, but none of the mice treated with 5 Gy showed donor
engraftent. The results indicate that the peripheral tolerance protocol does not lower
the radiation requirement in autoimmune-prone NOD mice.
Table 8: DST plus Anti-CDI54 mAb and Bone Marrow Regime Does Not Facilitate
Induction of Hematopoietic Chimerism in NOD Mice Using C57BL/6 Donors with Low-dose
Iradiation
Percentage
Anti- Bone Bone Number of of Donor-Radiation DST donor CD154 Marrow Marrow Chimeric Mice Origin(Gy)
mAb Donor Dose
(%)
PBMCs in
Chimeric
Mice
---
C57BL/6 25x 1 0 515 99.
C57BL/6 C57BL/6 25xl0 315 99,
C57BL/6 25xl0 015
---
C57BL/6 C57BL/6 25xl0 015
Legend to Table 8: NOD (H2 mice were transfused with 25 x 10 C57BL/6 (H2 bone
marrow cells on Day O. They were also iradiated with 6 or 5 Gy on Day O. Half the mice were given
C57BL/6 DST and injected intraperitoneally with 4 injections of anti-CDl54 mAb at 0.5 mg per
injection on days -
, -
, 0, +3 (relative to bone marrow transplantation on day 0), The other halfwere
injected with 2 injections of anti-CD 154 mAb at 0,5 mg per injection on days 0 and +3. PBMCs from
the hosts were analyzed 6 weeks after bone marrow transplantation.
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Summary
A protocol used to induce peripheral tolerance to allogeneic skin and islet grafts is
shown to be effective in enhancing the engraftment of allogeneic bone marrow cells to
induce hematopoietic chimerism with only a low dose of radiation conditioning. As
shown in Table 4, the previous protocol consisting of bone marow cells and anti-CDl54
mAb did not induce allogeneic chimerism at lower radiation doses even when the bone
marrow cell dose was increased to almost 10 times the standard dosage.
incorporating DST into the protocol, we were able to induce mixed allogeneic chimerism
in 3 different strains of mice (BALB/c, BI0.BR and CBA/J) using C57BL/6 donors with
as little as 1 Gy of radiation. Even at this low radiation dose, the percentage of donor-
origin cells in the hosts was moderately high, ranging from 21-57%, However, the
extension of this protocol to NOD mice did not reduce the radiation required for the
generation of chimerism.
CHAPTER V
ALLOGENEIC CHIMERISM WITHOUT MYELOABLATIVE
PRE-TREATMENT
Introduction
The previous experiments documented that DST plus anti-CDl54 mAb can
greatly reduce the radiation required to induce hematopoietic chimerism using fully
allogeneic bone marow cells, A major objective in stem cell transplantation is to find a
protocol using the least amount of myeloablation to the host, but still lead to engraftment
of the donor stem cells, So , the hypothesis is that by first inducing peripheral tolerance
using DST plus anti-CDl54 mAb , allogeneic chimerism could be established using no
myeloablative treatment (i. e. no radiation). I also explored the requirements and cellular
mechanisms involved in the induction of allogeneic chimerism using this protocol.
Results
Establishment of Allogeneic Hematopoietic Chimerism in the Absence of
Host Myeloablative Conditioning in BALB/c Mice
We first tested our peripheral transplantation tolerance-induction protocol for its
ability to facilitate the generation of hematopoietic chimerism in BALB/c (H2 mice.
BALB/c mICe were treated with a C57BL/6 (H2 DST plus anti-CD 154 mAb and
injected 7 days later with 50 x 10 allogeneic C57BL/6 bone marrow cells in the absence
of any myeloablative conditioning. As shown in Table 9 (Group 1), 89% of treated
BALB/c mice became chimeric. The percentage of donor-origin PBMC in these mice 8 to
9 weeks after bone marrow transplantation averaged 9%. PBMC were re-analyzed at
intervals 12 to 30 weeks after transplantation, and this level of chimerism remained stable
throughout the period of observation (data not shown). There was no evidence of
chimerism in any BALB/c mice treated with bone marrow and anti-CDl54 mAb
monotherapy (Table 9 , Group 2).
Table 9: Hematopoietic Chimerism in Recipients of C57BL/6 Bone Marrow
Anti- Bone Donor Origin
Group Host Myeloablative DST CD154 Marrow Dose Frequency of PBMC inConditioning
mAb (x 10 Chimerism 
(%)
Chimeric Mice
(%)
BALB/c Yes Yes 17/19 (89%) 9.2 :i 3.2
BALB/c Yes 0/10 (0%)*
BALB/c Yes Yes Yes 5/5 (100%) 37.2 :i 4.
CBAJJ Yes Yes 17/25 (68%) 3 :i 4.5
CBAJJ Yes 0/9 (0%)*
CBAJJ Yes Yes 100 5/5 (100%) 16.5 :t 5.
CBAJJ Yes Yes Yes 9/9 (100%) 35.6 :i 5.2%
B 1O. Yes Yes 14/14 (100%) 16.9:i 12.4
BlO. Yes 15/15 (100%) 19.7:i 10.
BlO. 0/8 (0%)*
Legend to Table 9: BALB/c (H2 ), CBAJJ (Hi') or B 1O.BR (Hi') mice were randomized to
the indicated treatment groups and injected with C57BL/6 (H2 bone marrow cells at the dose
indicated on day O. Mice treated with a donor-specific transfusion (DST) received 10 C57BL/6 spleen
cells on day -7 relative to bone marrow transplantation. Mice treated with anti-CD 154 mAb received 4
doses of 0.5 mg intraperitoneally on days -
, -
, 0 , +3. Hematopoietic chimerism was defmed as the
presence of ).0.5% donor-origin (H2- ) PBMC as described in Methods. *The percentage of donor-
origin PBMC in all non-chimeric mice was in all cases below the limit of detection (.:0.5%),
..'1
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The Levels of Hematopoietic Chimerism Achieved Generate Donor-Specifc
Transplantation Tolerance in the Absence of GVHD
Although we achieved allogeneic hematopoietic chimerism, the levels of
chimerism were relatively low. To document that these levels were suffcient to generate
transplantation tolerance, subsets of both chimeric and non-chimeric BALB/c mice from
Table 9 (Groups 1 and 2) were transplanted with C57BL/6 skin allografts 9 weeks after
injection of C57BL/6 bone marrow. Median survival time (MST) of skin allografts in the
chimeric mice was /89 days (38 , /56 , 80, 80, /98 , /98 , /112, /112 days). In contrast
most of non-chimeric mice rejected skin allografts rapidly (11 , 11 , 11 49 days
p':O. OOI). To document that this state of transplantation tolerance was donor-specific
additional chimeric BALB/c mice were transplanted 9 weeks after bone marrow
transplantation with third-party skin allografts from CBA/J donors. Surival of these 4
allografts was very brief, all ofthem rejecting on day 14 (p=N.S, vs. non-chimeric mice).
Animals were observed for signs of GVH throughout the period of observation
(up to 30 weeks). There was no sign of ilness in any chimeric bone marrow recipients
given the anti-CDl54 mAb regimen. Thirty weeks after transplantation, 4 chimeric
BALB/c mice were selected at random and studied histologically. There was no evidence
ofGVHD in samples of skin, liver, or small or large intestine in any of the mice.
Allogeneic Stem Cell Engraftment Using anti-CD154 mAb and DST but no
Myeloablation can be Achieved in CBA/J and B10.BR Recipient Mice
To determine if the engraftent of allogeneic bone marrow cells in mice treated
with DST plus anti-CDl54 mAb is strain-dependent, we performed the same experiment
V ..
usmg two different strains of mice as recipients. When tested 8 to 9 weeks after
administration of a C57BL/6 DST, anti-CDl54 mAb , and C57BL/6 bone marow cells
68% of CBA/J mice (Table 9, Group 4) and 100% of BI0.BR mice (Group 8) became
chimeric. In both cases, the frequency of chimerism was statistically similar to that
achieved using BALB/c recipients (Group p=N. ). The percentages of donor-origin
PBMCs in chimeric CBA/J mice ( 8%) were similar to those in chimeric BALB/c mice
(p=N. ) but levels in both BALB/c and CBA recipients were signficantly less (pO:O.Ol)
than levels achieved in B 1 O,BR mice ( 17%).
Like BALB/c mice, CBA/J recipients of bone marow and anti-CDl54 mAb but
no DST did not become chimeric (Table 9 , Group 5). In contrast, BI0.BR mice treated in
the same way uniformly became chimeric (Group 9). As was true for BI0.BR recipients
given both anti-CDl54 mAb and a DST (Group 8), 20% of their PBMC were of donor-
origin. In both groups of B 1 O.BR chimeras, the percentage of donor-origin cells vared
widely from 2.6 to 46%, B 1O.BR mice treated with a bone marrow graft but neither anti-
CD154 mAb nor DST failed to become chimeric (Group 10),
To determine if the result obtained from B 10.BR (Table 9 , Group 9) was due to
the similarities in the minor MHCs between the donor and host, a strain of mice that did
not share a common ancestor was used as a donor. DBA/2 (H2 cells were injected into
B 10.BR hosts. As shown in Table 10, all of the B 10.BR recipients of DBA/2 DST plus
anti-CDl54 mAb and DBA/2 bone marow cells readily exhibited engraftment with
40% of their PBMC being of donor-origin (Group 2). Interestingly, even though all of
the mice that received just anti-CDl54 mAb and DBA/2 bone marrow also tued
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Table 10: Hematopoietic Chimerism in BIO,BR Recipients ofDBA/2 Bone Marrow
Bone Marrow Frequency of Percentage of DonorGroup Host DST Donor Donor Chimerism 
(%)
Origin PBMC in
Chimeric Mice 
(%)
B IO. C57BL/6 C57BL/6 515 (100%) 20.2:J 8,
BI0, DBA/2 DBA/2 515 (100%) 39, 1 :J 20.4
BI0. None DBA/2 414 (100%) 1 :J 0,
Legend to Table 10: BI0.BR (Hi) mice were randomied into 3 groups, All groups were
injected intraperitoneally with 4 doses of 0,5 mg anti-CDl54 mAb on days -
, -
, 0, +3, The control
group received the standard protocol ofDST on day -7 and 50 x 10 bone marrow cells on day 0 from
C57BL/6 donors. The 2 group received the same treatment, but from DBA/2 (H2 donors. The 3
group just received bone marrow cells from DBA/2 donors. Chimerism was defmed as 0.5% donor-
origin PBMC as determed by flow cytometr analysis.
chimeric , the percentage of donor-origin cells was drastically smaller ( 6%) than Group
2 (p 02) and also than those that received anti-CDl54 mAb and C57BL/6 bone marrow
without DST (Table 9 , Group 9
, p
03).
Increasing Bone Marrow Cell Dose or Adding Minimal Myeloablative
Conditioning Increases Levels of Chimerism
Because hematopoietic chimerism can be established in the absence of
myeloablative conditioning if very high numbers of bone marow cells are transplanted
(142;143), we studied the effect of increasing the donor inoculum in mice treated with
both DST and anti-CDl54 mAb. Transplantation of 100 x 10 C57BL/6 bone marow
cells into CBA/J recipients was associated with uniform generation of chimerism (Table
, Group 6), and the percentage of donor-origin PBMC in these mice was on average
double that observed in CBA/J recipients of 50 x 10 C57BL/6 cells (Table 9 , Group 4
03).
The addition of minimal myeloablation also improved outcome. Both BALB/c
(Table 9, Group 3) and CBA/J (Group 7) recipients uniformly became chimeric if treated
with 1 Gy of whole body irradiation prior to DST , anti-CDl54 mAb, and infusion of 50 x
C57BL/6 bone marrow cells. In both cases , donor-origin cells comprised more than a
third of the PBMC population 6-7 weeks after bone marow injection, and these
percentages were statistically signficantly greater than the percentages achieved without
conditioning (Table 9 , Groups 1 and 4, po:O.OOI for both comparisons).
Timing ofDST and anti-CD154 mAb Treatment is Important for Generation of
Allogeneic Chimerism
In studies of solid organ transplantation tolerance induction, we have shown that
administration of DST plus anti-CDl54 mAb leads to the deletion of peripheral host
alloreactive CD8+ T cells, an effect that is maximal 3 days after the initiation of
treatment (140). We hypothesized that deletion of host alloreactive CD8+ T cells would
define the optimal time point at which allogeneic bone marow chimerism could be
achieved in the absence of myeloablative conditioning. We tested this hypothesis by
varying the timing ofDST plus anti-CDl54 mAb treatment in relation to C57BL/6 bone
marow transplantation into CBA/J recipients. In these experiments, the first of the four
injections ofanti-CDl54 mAb was always given immediately before the DST.
When DST was given 10 or 14 days before bone marow transplantation, 60%
and 80% of recipients, respectively, became chimeric (Table 11 , Groups 1 and 2); this
rate of success was comparable to that achieved when DST was injected 7 days before
transplantation (68%, Table 9, Group 4, p=N. ). The percentage of donor-origin PBMC
.,,
Table 11: Hematopoietic Chimerism in CBAlJ Recipients of C57BL/6 Bone MaITow
Group Day of DST Frequency of Percentage of Donor OriginInjection Chimerism 
(%)
PBMC in Chimeric Mice 
(%)
4/5 (80%) 10,2:1 1.9
3/5 (60%) 1004:1 4.
0/5 (0%)*
0/5 (0%)*
Legend to Table 11: Groups of CBAlJ (Hi') mice were randomied and transplanted with 50 x
C57BL/6 (H2 bone marrow cells on day O. All mice also received a single C57BL/6 DST
consisting of 10 spleen cells on days -
, - , -
, or - 14 relative to bone marrow transplantation. In
addition, all mice were injected intraperitoneally with 4 doses of 0.5 mg anti-CDl54 mAb on days 0
, +7 , and +10 relative to the DST. The temporal relationship of the DST and anti-CDl54 mAb
injections was the same as in Table 9; only the timing of the bone maow graft was varied. Chierism
was defined as the presence of ::0.5% donor-origin (H2- l PBMC 6 weeks after transplantation.
p':O. OI VS. Table 9, Group 2.
detected 6 or more weeks after transplantation in the mice that became chimeric was
10%, irrespective of the timing of the DST.
In contrast, when DST was injected 5 or days before bone marrow
transplantation, no recipients became chimeric (Table 11 , Groups 3 and 4). Given that
host alloreactive CD8+ T cells are deleted in mice treated with DST plus anti-CDl54
mAb at these time points (140), the result was unexpected.
Summary
The induction of peripheral tolerance before donor bone marow transplantation is
shown to facilitate the establishment of allogeneic chimerism without the need for
radiation pre-treatment. The protocol is shown not to be strain-specific as two other
strains of mice are also able to engraft donor stem cells without myeloablation, The
establishment of chimerism also induced transplantation tolerance, as expected,
Interestingly, a minimum of 7 days was required between the star of the peripheral
tolerance protocol and donor bone marrow transplantation to achieve allogeneic
chimerism,
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CHAPTER VI
MECHANISMS REGULATING ALLOGENEIC STEM CELL
ENGRAFTMENT IN NON-MYELOABLA TED HOSTS
Introduction
The data presented in Chapter V clearly demonstrate that allogeneic
hematopoietic chimerism can be generated without cytoreductive conditioning using a
peripheral transplantation tolerance protocol consisting ofDST and anti-CDl54 mAb. In
an effort to determine the mechanism involved in the induction and maintenance of this
chimeric state, I employed TCR transgenic mice to determine the fate of the alloreactive
CD8+ T cells in the host. I also used depleting antibodies to determine the cell subsets
required for engraftment and rejection of donor bone marow cells. The hypothesis is
that the induction and maintenance of the chimeric state not only involves the permanent
deletion of alloreactive CD8+ T cells in the host, but may also involve the regulation of
other cell populations.
Results
The Combination of DST, Anti-CD154 mAb, and Bone Marrow Engraftment Leads
to Permanent Deletion of Host Alloreactive CDS Peripheral T Cells
In studies of peripheral tolerance induction using DST plus anti-CDl54 mAb , we
have documented that host alloreactive CD8+ T cells are deleted rapidly, that these cells
then reappear over time, and that their reappearance is associated with rejection of
healed-in skin allografts (139). Given the apparent permanence of hematopoietic
chimerism in mice treated with DST, anti-CDl54 mAb, and bone marow, we
hypothesized that establishment of chimerism would lead to permanent deletion of
peripheral alloreactive CD8+ T cells. To test this hypothesis, we used KB5 synchimeric
mice. These mice circulate small numbers of TCR transgenic alloreactive CD8+ T cells
that are continuously replenished over time as newly generated KB5 T cells are released
from the thymus (139).
KB5 synchimeric mice were randomized into 4 groups. Mice in group 1 (Figue
6) were untreated. Mice in Groups 2 and 3 received anti-CDl54 mAb plus either a
C57BL/6 bone marrow (Group 2) or C57BL/6 spleen cell DST (Group 3). Mice in
Group 4 received anti-CDl54 mAb plus a C57BL/6 spleen cell DST and C57BL/6 bone
marow,
The level of alloreactive DES CD8+ T cells in the peripheral blood of these 4
groups of mice is shown in Figue 6. The level of DES CD8+ T cells in control mice
-0 Untreated Controls (Group 1, N=7)
-0 anti-CD154 mAb + Bone Marrow (Group 2 , N=8 , none chimeric)
-& anti-CD154 mAb + Transfusion (Group 3 , N=8, none chimeric)
-0 anti-CD154 mAb + DST + Bone Marrow (Group 4 , N=6, all chimeric
Weeks
Figure 6. Permanent Deletion Of Allo-Reactive T Cells In Chz'merz'c Mz'ce. Deletion of
peripheral host alloreactive CD8+ T cells. KB5 CBA synchieras were randomied into 4 cohorts.
Group 1 was untreated. Group 2 was injected with 4 doses of anti-CD 154 mAb on days 0, +3 , +7, and
+ 1 0 relative to injection of 50 x 10 C57BL/6 bone maITOW cells on day 7. Group 3 received 4 doses of
0.5 mg of anti-CD 154 mAb at the same intervals plus a transfusion of C57BL/6 spleen cells on day 
Group 4 received a donor-specific transfusion of C57BL/6 spleen cells on day 0 and anti-CD 154 mAb
on days 0, +3 , +7, and +10 relative to injection of 50 x 10 C57BL/6 bone maow cells on day 7. The
percentage of DES CD8+ cells in the blood was determned on day 0 before any treatment and then at
the indicated times. With two weeks of treatment, the percentage ofDES CD8+ cells was significantly
lower in all treatment groups compared with controls (p.:O.OOl). Thereafter, the percentage of
DES CD8+ cells in Groups 2 and 3 tended to rise towards that observed in controls, but even at week 15
the percentage remained less than in controls (p':O. OOl). In contrast, the percentage ofDES+CD8+ cells
in Group 4 remained extremely low throughout the course of the experiment, and at week 15 was
significantly lower than in all other groups (p':0. 001 for each comparison). In 5 of 6 mice, in Group 4
no alloreactive CD8+ T cells were detected (.:0.2%) for the duration of experiment. In one mouse, 2.
DES CD8+ T cells were detected at week 9 , but were undetectable (.:0.2%) in this mouse when
analyzed at week 15. With respect to chimerism, defined as 0.5% donor-origin (H2- l PBMC 9
weeks after transplantation, all mice in group 4 were chimeric and none in Groups 2 or 3 were chimeric.
durng the period of observation was 5 to 5%; these levels are comparable to those
we have reported previously in this model system (139).
None of the mice in Groups 2 and 3 became chimeric; no donor-origin cells being
detectable at any time point throughout the 15 week period of observation. As expected
and consistent with previous reports (139), the level of alloreactive DES CD8+ T cells in
mice treated with anti-CDl54 mAb and a splenocyte DST (Group 3) was much lower
within two weeks of transfusion (- 8%). Thereafter the levels rose slowly and had
recovered to 2.4% by week 15. The behavior of mice treated with anti-CD154 mAb and
bone marrow (Group 2) was similar, although the initial decline was less dramatic than
that associated with the use of a splenocyte DST.
The results for the mice treated with anti-CDl54 mAb , a splenocyte DST, and
then with a bone marow allograft (Group 4) were much different. As expected, 6 of 8
(75%) became chimeric, The percentage of donor-origin PBMC 9 weeks after
transplantation was high (22.3 :: 13.2%) and remained at about this level throughout the
15 week period of observation, In striking contrast to the outcome in the other Groups
the level of DES CD8+ T cells in the six chimeric mice fell within 2 weeks to levels that
were below the limit of detection and remained at that low level throughout the period of
observation (p::0.001 vs. all other groups at week 15),
Normal Distribution ofCD4 and CD8 Cells in the Thymus ofKB5
Synchimeric Mice
The long-term absence of peripheral alloreactive DES+CD8+ cells in mice with
hematopoietic chimerism suggested that they might be undergoing intrathymic deletion.
Before proceeding to test this possibility, we first analyzed overall thymic maturation in
the untreated KB5 synchimeric mouse, It was important to do so because the KB5
transgenic mice used to generate synchimeras have an abnormally large population of
single-positive CD8+ cells in the thymus (156). We observed, however, that KB5
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synchimeric mice exhibit a normal distrbution oftotal CD4+ and CD8+ thymocytes (157-
159). The thymocytes of untreated KB5 synchimeric mice consisted of a large population
of double-positive cells (81.5 :t 4.3%, N=14) and smaller populations of CD4 CD8
single positive cells (9.4 :t 1.4%, N=14) and CD4 CD8+ (4.4 :t 1.6%, N=14) single
positive cells. Representative histograms are shown in Figure 7, These percentages of
single and double positive thymocytes are typical of those observed in normal untreated
adult mice (158;160;161).
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Figure 7. Intrathymic Deletion Of Alloreactive T Cells In Chimeric Mice. Intrathymc
deletion of host alloreactive DES CD8 CD4- thymocytes. KB5 CBA synchimeras were randomied
into 2 groups. Group 1 (upper panels) was left untreated. Group 2 (lower panels) was injected with a
C57BL/6 DST on day -7 and anti-CD 154 mAb on days -
, -
, 0, and +3 relative to injection of 50 x 10
C57BL/6 bone marrow cells on day O. Thym were recovered 35 weeks after bone marrow
transplantation and analyzed by flow microfluorometr for the percentage of DES CD8+CD4-
thymocytes as described in Methods. Shown in the left column are representative dot plots; the
perpentage of cells expressing CD4 and CD8 is indicated in each quadrant. Shown in the right colum
are histograms indicating the number of DES+ cells in the CD8+CD4- quadrant. Shown are
representative data; the complete dataset is given in Table 12.
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DES CDS CD4 Thymocytes are not deleted by Treatment with DST plus
Anti-CD154 mAb
Having determined that the overall distribution of thymocyte CD4+ and CD8
phenotypes in synchimeric mice is normal, we next measured the percentages of
DES CD8+ thymocytes following co stimulation blockade and splenocyte transfusion.
Before any treatment, the percentage of CD8+ CD4- thymocytes that were also DES+ was
26.4 :t 20,8% (Table 12, Group 1). DES+CD8 CD4- thymocytes were also readily
detectable at statistically similar levels 4 and 7 days after treatment with DST and anti-
CD154 mAb (Table 12, Groups 2 and 3 , p=N. ), In contrast, it is known that that
peripheral DES CD8+ cells are deleted within 3 days of treatment with DST plus anti-
CD154 mAb, well before graft placement (140),
Bone Marrow Cell Engraftment in Mice Treated with DST plus Anti-CD154
mAb Leads to Intrathymic Deletion of DES CDS CD4 Cells
We next tested the hypothesis that successful generation of hematopoietic
chimerism subsequent to treatment with DST and anti-CDl54 mAb would lead to the
deletion of DES CD8 CD4- alloreactive thymocytes. As shown in Table 12, 15 days
after bone marrow transplantation the percentage ofDES CD8 CD4- thymocytes in mice
treated with DST and anti-CDl54 mAb (Table 12 , Group 5) was 50% less than in age-
matched mice that had been given DST and anti-CDl54 mAb but no graft (Group 4), but
at this time point the difference was not statistically significant (p=0.08). By 21-30 days
after bone marrow injection, it was possible to distinguish chimeric and non-chimeric
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Table 12: Hematopoietic Chimerism and Host Alloreactive CD8+ T Cells in KB5
Synchimeric Recipients of C57BL/6 Bone Marrow
Time of Analysis Host CD8 CDr
Group Transfusion Bone Marrow Chimeric Relative to Thymocytes thatDonor Donor completion of
were DEsr 
(%)
treatment (Days)
Same approximate
None None age as group 1 26.4 :: 20.
No treatment given
C57BL/6 None 3 d 18. 6:: 4.
C57BL/6 None 0 d 25.7:: 11.
C57BL/6 None +15 d 38.2:: 21.
C57BL/6 C57BL/6 *See legend +15 d 16.2:: 13.
C57BL/6 None +21-30 d 30.4:: 13.
C57BL/6 C57BL/6 +21-30 d 30.4:: 8.
C57BL/6 C57BL/6 Yes +21-30 d All .:O,
None None
Age matched, never
8:: 0.
treated
C57BL/6 C57BL/6 35 weeks 4.4, 18.
C57BL/6 C57BL/6 Yes 35 weeks All ':0.
Legend to Table 12: CBAlJ (H2 ) mice 4 weeks of age were iradiated (2 Oy) and injected
with bone marrow from KB5 CBAlJ TCR transgenic donors as described in Methods. Eight to 10
weeks later, with no additional iradiation, these KB5 CBAlJ synchimeras received a donor-specific
transfusion consisting of 10 C57BL/6 (H2 ) spleen cells on day -7 plus 4 intraperitoneal doses anti-
CD154 mAb (0.5 mg/dose) on days -
, -
, 0, +3 relative to intravenous injection of 50 x 10 C57BL/6
bone marrow cells on day O. Thym were recovered at the indicated time points relative to marrow
transplantation on day 0 and the percentage of host anti-donor alloreactive DES CD8 CD4- thymocytes
was measured by flow microfluorometr. a: p=N,S. vs. groups 2 and 3. b: p=0.08 vs. group 4. c: p':O.
vs, groups 6 and 7. d: p':O,05 vs. combined groups 9 and 10. *At the 15 day time point, it cannot
reliably be detennned if mice are chimeric.
recipients. At this time point levels of DES CD8 CD4- thymocytes remained at high
baseline levels in both mice that had received DST plus anti-CDl54 mAb but no graft
(Table 12, Group 6) and in mice that had received DST plus anti-CDl54 mAb plus a
graft but had not become chimeric (Group 7). In contrast, DES CD8 CD4- thyrocytes
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were undetectable (":0.3%) in all chimeric mice (Group 8 , p":O.OI vs, both Groups 6 and
7),
Additional mice were studied 35 weeks after treatment to assess the durability of
alloreactive thymocyte deletion, We first noted that the percentage of DES CD8 CD4
thymocytes in age-matched but untreated synchimeras had spontaneously fallen over
time, but were nonetheless readily detectable. The decline was from 26% at baseline
(Table 12, Group 1) to 3% 8 to 9 months later (Table 12, Group 9, p=O.OI).
DES CD8 CD4- thymocytes were also readily detectable in two recipients ofDST, anti-
CD154 mAb , and bone marrow that had not become chimeric (Group 10), In contrast, no
DES CD8 CD4- thymocytes could be detected in any of three recipients of DST, anti-
CD154 mAb, and bone marow that had become and remained chimeric (Table 12
Group p":0.05). A representative histogram documenting the disappearance of
DES CD8 CD4- thymocytes in one of the chimeric mice from Group 11 is shown in
Figure 7. Although lacking in DES CD8 CD4- thymocytes , the thymi of these mice 35
weeks after bone marrow transplantation were clearly allochimeric, The presence of both
host (H2- ) and donor (H2- ) thymocytes was confirmed by flow micro fluorometry
(data not shown).
MHC-Matching of the DST and Bone Marrow Donors is not Required for
Allogeneic Bone Marrow Engraftment in Normal Mice
Induction of peripheral transplantation tolerance using DST and anti-CDl54 mAb
requires that the MHC of the transfusion donor be the same (i. donor specific ) as that
. .
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of the graft donor (138). We hypothesized that successful generation of hematopoietic
chimerism using our protocol would also require MHC-matching of the transfusion and
bone marow cells e. that the transfusion had to be "donor-specific , To test this
hypothesis CBAlJ mice (H2 were treated with a C57BL/6 (H2 non-donor specific
spleen cell transfusion plus anti-CDl54 mAb and then injected with BALB/c (H2 bone
marrow cells. Unexpectedly, all became chimeric (Table 13 , Group 1), To verify this
unexpected outcome, we reversed the DST and bone marow donors. CBA mice (H2
were treated with BALB/c (H2 spleen cell transfusion plus anti-CDl54 mAb and then
injected with C57BL/6 (H2 bone marow cells. Again, the majority (90%) of these mice
became chimeric (Table 13 , Group 2).
Reduction of High Numbers of Host Alloreactive CDS+ T Cells is Required
for Bone Marrow Engraftment in KB5 Synchimeras
To begin to determine the role of the spleen cell transfusion in facilitating
subsequent engraftent of bone marow cells, we used KB5 synchimeras. In addition to
circulating their normal complement of alloreactive T cells, these mice also circulate
large numbers (6-8%) of DES CD8+ alloreactive (anti-H2- y T cells (140). Using our
standard protocol, which is known to delete DES CD8+ peripheral T cells (140), we
observed that 2 of 3 KB5 synchimeras given a C57BL/6 DST, anti-CDl54 mAb , and
C57BL/6 bone marow cells became chimeric (Table 13, Group 3), Confirming the
results obtained in normal CBAlJ mice (Group 1), all KB5 synchimeras treated with
C57BL/6 spleen cell transfusion plus anti-CDl54 mAb and then given BALB/c (H2
bone marow became chimeric (Group 4). We then reversed the MHCs of the transfusion
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Table 13: DST Facilitates Hematopoietic Cell Engraftrent by Both Allo-specific and Allo-
non-specific Mechanisms
Bone Marrow Frequency of Percentage of DonorGroup Host DST Donor Donor Chimerism 
(%)
Origin PBMC in
Chimeric Mice 
(%)
CBAlJ C57BL/6 BALB/c 9/9 (100%) 8:! 0,
CBAlJ BALB/c C57BL/6 9/10 (90%) 7.4 :! 2.
KB5 CBAlJ C57BL/6 C57BL/6 2/3 (67%) 22.1 :! 10.4
Synchimera
KB5 CBAlJ C57BL/6 BALB/c 5/5 (100%) 27.1 :! 5.
Synchimera
KB5 CBAlJ BALB/c C57BL/6 0/4 (0%)* -:0.
Synchimera
Legend to Table 13: CBAlJ (H2') and KB5 CBAlJ TCR transgenic synchimeric mice (H2')
were injected intravenously with 10 spleen cells as a DST on day -7 and intraperitoneally with 4 doses
of 0,5 mg anti-CD 154 mAb on days -
, -
, 0, +3 relative to intravenous injection of 50 x 10 C57BL/6
(H2 or BALB/c (H2 bone marrow cells on day O. Chimerism was defined as ;;0.5% donor-origin
PBMC as determed by flow cytometr analysis, *pO:O.Ol vs. Group 4.
and bone marrow donors and found, in contrast, that no KB5 synchimeric mice became
allochimeric when treated with BALB/c spleen cell transfusion plus anti-CDl54 mAb
and then given C57BL/6 (H2 bone marow cells (Table 13 , Group 5 , pC:O. Ol vs. Group
4). The result suggests that, in the presence of large numbers of allospecific T cells in the
recipient, as in the synchimera with large numbers of anti-H2- T cells, the transfusion
may need to be matched to that allospecificity.
Host CDS+ Cell Deletion is not Sufficient for Optimal Engraftment of
Allogeneic Bone Marrow Cells
We have previously shown that, in par, the role of DST in our costimulation
blockade protocol for peripheral tolerance induction is to enhance the deletion of host
alloreactive CD8+ T cells (139;140). The phenotyping analyses of KB5 synchimeras in
ch hematopoietic chimerism was generated successfully suggest that deletion of both
106
peripheral host alloreactive CD8+ T cells and host alloreactive thymocytes is required.
We next tested the hypothesis that host CD8+ T cell deletion is required but not suffcient
for establishing hematopoietic chimerism; we did so by replacing the DST in our protocol
with a depleting anti-CD8 mAb. We observed that the frequency of chimerism in
BALB/c recipients treated with anti-CD8 mAb and anti-CDl54 mAb before
transplantation ofC57BL/6 bone marow was much lower (22% Table 14, Group 1) than
in recipients treated with anti-CDl54 mAb and DST (Table 9 , Group 1 , p':O,OOI). The
result suggests that the role ofDST in facilitating engraftment of allogeneic bone marow
cells involves mechansms in addition to the deletion of host alloreactive CD8+ T cells.
Table 14: Frequency of Chimerism in BALB/c Recipients ofC57BL/6 Bone Marrow
Treated with Monoclonal Antibodies
DST Frequency of
Percentage of Donor
Group Recipient Treatment Origin PBMC inDonor Chimerism 
(%)
Chimeric Mice 
None Anti-CDS mAb 2/9 (22%)* 6:: 1.0
None Anti-CD 122 mAb 9/9 (100%)** S :: 2.4
C57BL/6 Anti-CTLA4 mAb 2/9 (22%)* S:: 2.
C57BL/6 Anti-CD4 mAb 6/9 (67%) 7:: 1.2*
C57BL/6 Anti-CD25 mAb 8/9 (S9%) 0 :: 1.6
Legend to Table 14: BALB/c mice were randomied and injected with 50 x 10 C57BL/6
(H2 bone marrow cells on day O. All mice were injected intraperitoneally with 4 doses of 0.5 mg anti-
CD154 mAb on days -
, -
, 0, +3 relative to bone marrow transplantation. In the groups indicated, anti-
CD8 (0.5 mg/dose), anti-CD4 (0.5 mg/dose), or anti-CTLA4 (0.075 mg/dose) mAb was injected
intraperitoneally on days -
, -
, and -5 relative to bone marrow transplantation. Anti-CDI22 mAb (1
mg/dose) was injected intraperitoneally on days -8 and - 1 relative to bone marrow transplantation. Mice
in Groups 3 , 4, and 5 received a single donor specific transfusion consisting of 10 C57BL/6 spleen
cells on day -7 relative to bone marrow cell transplantation, *pO:O.005 VS. Table 9, Group 1; **pO:O.005
VS. Group 1.
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Hematopoietic Chimerism is Established in Mice Treated with Anti-CDI54 mAb,
Anti-CDI22 , and Bone Marrow Cells
NK cells, which are CDI22 , are known to be important in the rejection of
allogeneic bone marrow (162- 165), CDl22 is expressed on most NK cells, activated
macrophages, and a subset of activated CD8+ T cells , and anti-CDl22 mAb has been
shown to delete NK cell activity in vivo (166-168), To begin to investigate the role ofNK
cell depletion in allogeneic bone marrow transplantation in mice treated with
costimulation blockade, BALB/c mice were given anti-CDl54 mAb, anti-CDl22 mAb
and 50 x 10 C57BL/6 bone marow cells. Surrisingly, hematopoietic chimerism was
established in 100% of these recipients (9/9, Table 14, Group 2). This rate of successful
engraftent is comparable to that achieved using DST in place of anti-CDl22 mAb
(89%, Table 9, Group 1 , p=N. ) and signficantly greater than that achieved using anti-
CD8 mAb in place ofDST (Table 14 , Group 1 , p':O, OI).
Interventions that Abrogate Peripheral Tolerance Induction Reduce
Engraftment of Bone Marrow
We have previously shown that injection of anti-CTLA4 mAb at the time of
peripheral tolerance induction with DST and anti-CDl54 mAb prevents deletion of
alloreactive CD8+ T cells and shortens skin allograft surival (138;140). Treatment with
anti-CD4 mAb at the time of tolerance induction also shortens skin allograft surival
(138). We therefore tested the hypothesis that these interventions would also interfere
with the generation of hematopoietic chimerism in bone marrow recipients treated with
DST and anti-CDl54 mAb. As shown in Table 14 (Group 4), treatment with anti-CD4
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mAb had little effect, and two thirds of recipients became chimeric , albeit with a level of
chimerism that was quite low ( 7%, p':O.OOI vs. Table 9 , Group 1). Similarly, in a
cohort of recipients treated with an anti-CD25 mAb known to delete CD4 CD25
regulatory T cells , nearly all (89%, N=9) became chimeric (Table Group 5). In these
mice the level of chimerism (6.0%) was greater than in the anti-CD4 treated mice
(p.:0.005), but not as high as in recipients treated with only DST and anti-CDl54 mAb
9%, Table 9, Group p':O, 025). Only in the case of treatment with anti-CTLA4 mAb
was there a significant reduction in the percentage of mice that became chimeric (22%,
Table Group 3), The results suggest that the mechanism by which the combination of
DST plus anti-CDl54 mAb generates peripheral transplantation tolerance is distinct but
overlaps with the mechanism by which it generates hematopoietic chimerism.
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Summary
Establishment of allogeneic hematopoietic chimerism leads to the generation of
central tolerance and donor-specific transplantation tolerance. Achievement of
hematopoietic chimerism in the absence of host myeloablative conditioning and
development of graft-versus-host disease (GVHD) would allow the widespread
application of stem cell transplantation in the clinic. I have developed a strategy to
achieve these goals in mice based on a co stimulation blockade-based peripheral
transplantation tolerance protocol using a donor-specific transfusion (DST) plus a brief
course of anti-CD 154 monoclonal antibody (mAb). This protocol leads to permanent islet
allograft surival, and prolonged skin allograft surival in mice and non-human primates.
When applied to stem cell transplantation, administration of a spleen cell transfusion as a
DST, anti-CDl54 mAb, and allogeneic bone marow cells permits establishment of
hematopoietic chimerism and central tolerance in the absence of GVHD. Hematopoietic
chimerism leads to the peripheral deletion of host alloreactive CD8+ T cells, and
intrathymic deletion of newly developing alloreactive CD8+ T cells. Deletion of
peripheral host alloreactive CD8+ T cells is not suffcient for the establishment of
chimerism. MHC-matching between the splenocyte transfusion and bone marow donors
is not required unless supraphysiological levels of host alloreactive CD8+ T cells are
present, suggesting that both donor-allo-specific and non-allo-specific mechanisms
regulate hematopoietic engraftment. Functionally, establishment of chimerism can 
modulated by agents that interfere with peripheral transplantation tolerance. I conclude
that it is possible to establish robust allogeneic hematopoietic chimerism in the absence
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of host myeloablative conditioning using a peripheral transplantation tolerance protocol
consisting ofDST , anti-CDl54 mAb , and hematopoietic stem cells.
. .., ,
t:.
111
CHAPTER VII
DISCUSSION
Experimental protocols for the induction of allogeneic chimerism have made
considerable advances since the landmark experiments by Owen and Medawar (104-
107), Curently, the transplantation of hematopoietic stem cells relies on the use of
myeloablative conditioning and immunosuppressive drgs, The severe conditioning
regime and the detrmental side-effects associated with the procedure limit the utilization
of allogeneic chimerism to patients afficted with fatal autoimmune diseases and
malignancies. Attempts to overcome the obstacles involved in stem cell transplantation
have led to a new wave of protocols focused on reducing the toxicity of the conditioning
treatment and removing the reliance on immunosuppressive drgs. The reduction in
morbidity and mortality associated with bone marrow transplantation would make
allogeneic chimerism a realistic clinical option for non-malignant tumors , autoimmune
diseases and organ transplantation.
Co stimulation blockade has been found to induce potent non-responsiveness in
donor-specific lymphocytes both in vitro and in vivo. The use of anti-CDl54 mAb to
block the costimulatory signals has proven to be effective in prolonging allogeneic grafts
such as pancreatic islets, hear and skin (134- 136; 13 8; 169- 171). Based on these results
the next step was to determine if anti-CDl54 mAb could also enhance the engraftment of
allogeneic bone marow cells and the induction of a chimeric state in the host. It was
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hypothesized that the induction of tolerance using anti-CDl54 mAb would significantly
reduce the toxicity of the conditionig regimen required for stem cell transplantation,
The progress of this thesis was determined by the level of toxicity of host
conditioning regimens required to establish allogeneic chimerism using anti-CDl54
mAb, The initial protocol involved the requirement for sub-lethal irradiation, but
enhancements in the protocol led to fuher reduction in radiation requirements until
eventually none was needed to induce chimerism. Furher analysis was performed to
determine the mechansm involved in generating and maintaining the chimeric state
without any myeloablative conditioning.
The results from my earliest work demonstrated that it was possible to generate
hematopoietic chimerism in mice transplanted with fully allogeneic bone marow using
the combination of sub-lethal irradiation and a brief course of anti-CDl54 mAb
comprising as few as 2 injections. Chimeric mice treated according to this early protocol
showed no evidence of GVHD despite the presence of a peripheral lymphoid
comparent almost entirely of donor origin. Chimeric mice also accepted donor-origin
skin and islet allografts.
The minimum dose of radiation required to generate chimerism differed between
the BALB/c and NOD/Lt strains. Chimerism could be generated with as little as 4 Gy in
BALB/c mice, whereas 6 Gy appeared to be the threshold in NOD/Lt mice. These
differences may reflect intrinsic differences between these strains with respect to overall
radioresistance. The thresholds for chimerism in BALB/c and NOD/Lt mice were roughly
proportional to the respective lethal radiation doses of 7 Gy and 10 Gy. The radiation
i' 
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doses required for chimerism may simply be those that achieve adequate, but not lethal
degrees of elimination of host hematopoietic cells.
The co stimulatory blockade produced by treatment with anti-CDl54 mAb exerted
two important effects. First, it lowered the dose of radiation required to achieve
chimerism in both of the strain combinations tested. The effect was to some extent
dependent on the overall dose of anti-CDl54 mAb administered, but the data indicate
clearly that prolonged treatment is not required. Administration of antibody on the day of
transplantation, just before the transfusion of cells, and again three days later was
suffcient to lead to hematopoietic chimerism.
The second major effect of co stimulatory blockade was on the occurence 
GVHD. Treatment with anti-CDl54 mAb was clearly associated with prevention of
GVHD in successful chimeras. With few exceptions, chimeras generated using irradiation
alone showed clinical characteristics of GVHD. In contrast, chimeras generated with the
same dose of radiation but with the addition of anti-CD 154 mAb showed no evidence 
this common complication, either acutely or chronically, for up to -11 months after bone
marow transplantation. These observations are consistent with previous reports
documenting that treatment with anti-CDl54 mAb can prevent GVHD in a model system
based on the transfer of alloreactive T cells (122;123;172). The work presented in this
thesis and from other laboratories generating chimeras using anti-CDl54 mAb (141- 143)
extend these earlier reports by demonstrating that donor T cells that continue to develop
in a fully reconstituted bone marow allograft recipient are tolerant of the host in the
absence of additional costimulatory blockade.
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The ability to generate fully allogeneic chimeric mice free of GVHD provided us
with the opportunity to perform additional studies in the areas of transplantation and
autoimmunty, As expected, based on the work of Owen (104) and many others (173-
175), allogeneic chimeric mice were able to accept donor origin allografts while retaining
the ability to reject third party grafts, Because skin contains a large number of
professional antigen presenting cells, skin allografts represent a robust stimulus for
rejection. Our observation of prolonged skin allograft surival in mice treated with
irradiation and anti-CDl54 mAb suggests that the tolerant state induced by our protocol
is robust and may support the transplantation of other vascular organs. It is important to
point out that treatment with anti-CDl54 mAb was required for uniform donor skin graft
tolerance in chimeric mice. The surival of skin allografts placed on anmals that had
been rendered chimeric by irradiation alone tended to be short, and in those cases where
skin grafts were not immediately rejected, GVHD appeared to be present. Several mice
with intact skin allografts died of GVHD.
In the case of type 1 diabetes, which occurs in the NOD mouse, the tissue affected
by autoimmunty is destroyed. Replacement of the affected tissue in these instances
requires procedures that overcome not only allorejection but also recurent autoimmune
destruction of the transplanted tissue. Diabetic NOD mice reject syngeneic islet grafts
(149), and only lethal 
irradiation followed by allogeneic bone marow transplantation has
prevented recurent autoimmunity in donor-origin islet allografts (101;103). The work
performed in this thesis now demonstrate that it is possible to cure autoimmune diabetes
in NOD/Lt mice by first generating hematopoietic chimerism using sub-lethal irradiation
' .
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plus a brief course of anti-CDl54 mAb and then transplanting donor-specific islets of
Langerhans. These grafts restored normoglycemia, and none failed durng the period of
experimental observation, The data suggest that the generation of allogeneic
hematopoietic chimerism based on sub-lethal irradiation and co stimulatory blockade can
prevent both allograft rejection and recurent autoimmunity,
In our continued effort to reduce the conditioning toxicity required for allogeneic
stem cell engraftent, we attempted to decrease the radiation requirement by increasing
the number of donor bone marow cells transplanted into the host. BALB/c mice
transplanted with 10 times the normal dosage of C57BL/6 bone marow cells did not
become chimeric when the radiation dosage was reduced by 2 Gy from the standard
protocol discussed above. Recently, other laboratories have been able to generate
allogeneic chimeras by using anti-CDl54 mAb and very high (2 x 10 ) numbers of bone
marow cells (142;143). A possible explanation is that one group used BI0.A and
C57BL/6 as donor and host, respectively. It could be argued that even though these mice
express different MHC haplotypes, these strains of mice share many non-MHC
background genes due to their common derivation from a C57BL ancestor (176).
Similarity in their non-MHC genes may have facilitated allogeneic hematopoietic cell
engraftment. The other group used fully-disparate strains of mice as donor and host, but
their protocol involved 8 doses of anti-CDl54 mAb and bone marow cells over a time-
period of 3 months. It may be that the constant dosage of transplanted donor bone
marow and the precise regimen of co stimulatory blockade exert effects on the extent and
durability of chimerism achievable using this approach.
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In an effort to reduce the conditioning toxicity without using large doses of donor
bone marow cells , we established a new protocol based on the induction of peripheral
transplantation tolerance. Our lab has previously documented that DST and anti-CDl54
mAb can induce peripheral tolerance in mice by the prolonged survival of skin allografts
(134;138;171) and the indefinite surival of pancreatic islets (135;136;169). The
peripheral tolerance protocol was shown to delete alloreactive CD8+ (139;140) and CD4
T cells (unpublished observation). Based on these data, we hypothesized that DST and
anti-CDl54 mAb could also prolong the survival of donor bone marrow cells by
peripheral tolerance to allow for their engraftent. The deletion of the alloreactive T
cells before bone marow transplantation was predicted to drastically reduce the radiation
requirements for allogeneic chimerism.
In BALB/c mice, at least 4 Gy of irradiation was required for bone marow
engraftent, but the introduction of DST into the protocol allowed for the generation of
mixed chimeras at only 1 Gy. Furher experiments using two other strains of mice
BI0.BR and CBAlJ, and stil using C57BL/6 as donor demonstrated that this protocol
was not strain-specific and could be used to tu varous strains of mice chimeric using
only 1 Gy of irradiation.
We next attempted to employ this protocol in the NOD mice in an effort to
address its clinical feasibility in the autoimmune setting, Unfortately, the addition of
DST into our protocol did not reduce the radiation requirement necessar for allogeneic
stem cell engraftent. To some extent, the outcome is not surrising. Our lab has
previously shown that co stimulatory blockade also fails to prolong skin allografts in non-
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diabetic NOD mice (149). It was initially hypothesized that this outcome was due to a
generalized defect in the response of NOD mice to tolerance induction resulting from
their autoimmunty, This concept seemed attractive as there are multiple imune defects
that could be involved in both the autoimmune phenotype and resistance to
transplantation tolerance phenotype. But recent data suggest that the two phenotypes can
be genetically separated (177; 178).
The promising results using low-dose irradiation with DST and anti-CDl54 mAb
to induce allogeneic chimerism prompted another examination of the protocol. A major
goal of the stem cell transplantation field is to induce engraftent using the least toxic
conditioning regimen. In terms of radiation requirement, the ultimate goal would be to
not use any radiation. Recently, a few publications have demonstrated that mixed
hematopoietic chimerism can be obtained in the absence of host conditioning
(142; 143; 179). However, these protocols require supraphysiological doses of bone
marow cells or the introduction of cytotoxic drgs, The data in this thesis document
that, even in the absence of any host conditioning, permanent mixed hematopoietic
chimerism and central tolerance are achieved using our peripheral transplantation
tolerance protocol to facilitate the engraftment of hematopoietic stem cells.
It has been shown that peripheral costimulation blockade-based protocols work to
varying degrees depending on the host strain (180). To confirm that the ability of DST
plus anti-CDl54 mAb to facilitate hematopoietic cell engraftent was not unique to the
BALB/c strain, we documented the ability of our protocol to establish hematopoietic cell
engraftment in the absence of host conditioning in two additional strains. Surrising, the
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BI0.BR mice were also found to turn chimeric with only C57BL/6 bone marow and
anti-CDl54 mAb; the BALB/c and CBA/J strains displayed no donor cells as expected.
! -
As discussed previously, it could be argued that the BI0.BR and C57BL/6 mice share
many non-MHC background genes due to their common C57BL ancestor (176). It is
known that minor MHC antigens are important determinants of hematopoietic graft
rejection, particularly by the innate immune system (181- 183). Results showing that the
level of chimerism in BI0.BR mice (treated with only anti-CDl54 mAb and bone
marow) was much lower using a completely mismatched donor (DBA/2) than the
C57BL/6 donors support this theory. But the fact that they were able to even become
chimeric with DBA/2 donors suggest that B 10.BR mice might be more susceptible to
chimerism induction than other strains. These results highlight the importance of using
the most diverse combination of strains to meet the strictest experimental test for
transplantation tolerance induction,
Of interest was the time interval required between induction of tolerance by
injection of DST plus anti-CDl54 mAb and the susceptibility of the host to
hematopoietic cell engraftent. Previous reports from our lab have shown that
alloreactive CD8+ T cells disappear from the circulation within 3 days after DST and
anti-CDl54 mAb treatment (139;140). This suggested that within 3 days of tolerance
induction, hosts should be susceptible to engraftment with hematopoietic stem cells.
However, we observed that 7 days was the minimum time between tolerance induction
and bone marrow injection that permitted establishment of chimerism.
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The kinetics of susceptibility to engraftment may be related to the ability of
splenocyte transfusion to induce a "non-specific" regulatory mechansm that facilitates
this process. Speculatively, this could be due to the development of "tolerogenic
dendritic cells and/or the production of regulatory cytokines by an immune system
activated in the presence of anti-CDl54 mAb, Supporting these possibilities are the
observations that dendrtic cells that ingest apoptotic cells (184) or are activated in the
presence of CD40-CD154 blockade, become tolerogenic cells that suppress immune
responses and secrete regulatory cytokines such as TGF-p and IL-I0 (85;185). 
alternative explanation may be a delayed deletion of host alloreactive T cells. It is known
that fully-activated CD8+ T cells migrate to non-lymphoid tissues where they become
memory cells (186;187). Incomplete activation in the presence of CD40-CD154
blockade may induce migration and initiate apoptosis of antigen-activated T cells, but
these cells may be rescued if re-stimulated with allogeneic bone marrow cells prior to the
final stages of apoptosis.
The establishment of central tolerance to alloantigens is thought to reqUIre
intrathymic and peripheral deletion of host alloreactive T cells 
(40). However, the
conclusion that establishment of hematopoietic chimerism generates central tolerance to
alloantigens by intrathymic deletion of alloreactive T cells is derived from indirect data
based on deletion of superantigen-reactive specific Vp subpopulations CD4+ T cells
(188), In an effort to study a system that contained a trace population of high-affnity
alloreactive T cells that not only circulated, but also developed in a normal
microenvironment, we developed a new model based on allo- TCR-transgenic
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hematopoietic chimeric recipients (synchimeras) (139). We designed these synchimeras
to respond to tolerance induction and mainten ce in a maner similar to that observed in
normal mice and to overcome the limitations inherent in V analysis and full TCR-
transgenic mice.
The results demonstrate that CD8+ alloreactive T cells from a "normal" immune
system are peripherally deleted upon chimerism induction using DST plus anti-CDl54
mAb and allogeneic bone marow without any radiation pre-treatment. As expected
DST and anti-CDl54 mAb alone induced temporary peripheral tolerance as shown by the
fall and then rise of the alloreactive KB5 T cells over time (139), However, the chimeric
mice displayed permanent deletion of the alloreactive T cells as shown not only
peripherally, but also intrathymically by the absence of CD8 CD4- KB5 thymocytes. Of
additional interest is our observation that our peripheral tolerance protocol in the absence
of bone marrow engraftment leads to transient deletion of peripheral but not intrathymic
alloreactive CDS+ T cells. Previous studies of skin allografts on mice treated with DST
and anti-CDl54 mAb have shown that graft survival is greatly prolonged, but seldom
permanent unless the recipient has been thymectomized (138). The inference has been
that the failure of graft maintenance is due to the release of new alloreactive thymic
emigrants into the periphery (139). The present results strongly suggest that this inference
is correct; they demonstrate that the generation of hematopoietic chimerism in effect
thymectomizes" recipients in a donor-specific maner. The data imply that central
tolerance is the essential complement to peripheral tolerance induction if allografts are to
be trly durable.
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Almost all of the protocols involved in allogeneic chimerism induction using anti-
CD154 mAb use bone marrow cells as the only source of donor antigens involved in T
cell co stimulatory blockade. They must use radiation, anti- T cell antibodies or very high
doses of bone marrow cells to achieve engraftment. A possible explanation of why these
additional measures are required is shown in Figure 6. Bone marow cells do not
efficiently delete allo-reactive T cells in conjunction with anti-CDl54 mAb. They
eliminate only 50% of the DES CD8+ T cells in the PBMC, whereas using splenocytes
as DST can remove almost all of the all ore active cells circulating in the host.
Additionally, peripheral tolerance experiments in our lab using bone marow cells as
DST are not as effcient as spleen cells as DST with anti-CDl54 mAb in prolonging skin
allografts (Tom Markees , unpublished). This observation provides fuher evidence that
alloreactive T cells are not entirely deleted when bone marow cells are the only source
of donor antigens in the tolerance protocols.
The results from Table 9 document, as expected from prevIOus studies of
peripheral tolerance induction (138), that anti-CDl54 mAb monotherapy in the absence
of DST is generally ineffective for generating hematopoietic chimerism. Surrisingly,
however, we found that a third-party (MHC-disparate) transfusion could be substituted in
some (but not all) cases for the standard donor-specific transfusion (DST). The key
observation for understanding this counterintuitive result was that an MHC-disparate
transfusion was effective only in normal recipients with a physiological (low) percentage
of alloreactive T cells. Synchimeric recipients, with their high level of alloreactive T
cells , became chimeric only if given a donor specifc transfusion, presumably to reduce
122
that number of alloreactive cells, In a normal CBA/J mouse, the number of natually
occurng T cells with this allospecificity is far fewer, and the requirement for donor
specificity of the transfusion was less strngent. In their aggregate, the results suggest that
the generation of hematopoietic chimerism using DST and anti-CDl54 mAb involves
both the deletion of host allospecific T cells and an additional, non-allospecific
suppressive mechanism,
Recent publications have reported that immunoregulatory cells can be generated
by blockade of the CD40:CD154 co stimulatory pathway in vivo or ex vivo (189;190).
These cells are able to inhbit both naIve and primed alloresponses. So , in addition to the
deletion of high-affnity CD8+ alloreactive T cells, our DST plus anti-CDl54 mAb and
bone marow protocol may also generate potent immunoregulatory cells to help facilitate
in inducing allogeneic chimerism. These cells may help regulate lower affnity
alloreactive T cells that may have escaped deletion. It has been demonstrated that
antigen-activated CD4+ T cells can enter a fuctionally unesponsive state (145;191) and
that these anergic/regulatory cells may be mediators of tolerance (192;193). More
recently, it has been shown that the suppressive effect of CD25+ regulatory cells is not
antigen-specific (194;195), So , it is possible that these regulatory cells are the reason for
the non-donor-specific induction of chimerism seen in the CBA/J mice in Table 13. But
the regulatory cells may not have been able to overcome the higher than normal level of
high-affnity alloreactive T cells present in the KB5 synchimera, Also , the addition of
depleting anti-CD25 mAb into the standard chimerism protocol in BALB/c mice using
C57BL/6 DST and bone marow yielded no adverse affect on chimerism induction.
J:.
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These results seem to imply that regulatory cells alone canot lead to the establishment of
allogeneic chimerism using a non-myeloablative protocol.
In order to understand further the mechanisms involved in the induction of
allogeneic chimerism using our protocol, we used depleting and blocking antibodies to
determine both the deletion and presence of specific cell populations required for the
process. Previous publications from our lab has shown that skin allograft surival using
DST and anti-CDl54 mAb depended mostly on the deletion ofCD8+ alloreactive T cells
and the presence of CD4+ T cells (138;140), , we hypothesized that the same
conditions would be required for the engraftment of donor bone marrow cells using DST
and anti-CDl54 mAb.
Interestingly, the replacement of DST with depleting anti-CD8 mAb, which
prolonged skin allograft surival (140), did not fully facilitate the induction of chimerism.
The fact that 2 mice did display donor-origin cells in their PBMC led us to believe that
the deletion of alloreactive CD8+ T cells is a major step required in the process but not
the sole requirement. Therefore, we next tested the possible role ofNK cells, which have
been shown to participate in the rejection of allogeneic bone marow cells in lethally
irradiated mice (196- 199), In an effort to deplete NK cells (and also activated CD8+ T
cells), we decided to use anti-CDl22 mAb (TM-Pl), CD122 is preferentially expressed
on a subpopulation of CD8+ T cells, activated macrophages and almost all NK cells (200-
202). Anti-CDI22 mAb has been shown to selectively eliminate natual killer (N) cells
and also signficantly reduce cytotoxic T cell (CTL) activity. By substituting DST with
anti-CDl22 mAb in our protocol, we were able to establish allogeneic chimerism in all of
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the BALB/c mice at levels of donor-origin cells similar to that observed in the control
group. Because CD154 is also expressed on NK cells, we hypothesize that engraftent
of allogeneic bone marrow cells in non-myeloablated hosts requires not only the deletion
of alloreactive CD8+ T cells, but also inactivation of host NK cells, But the possibility
exists that anti-CDl22 mAb is affecting activated macrophages , as they too also express
CD122 , to regulate stem cell engraftent. In order to further explore the role NK cells
may have in chimerism induction without myeloablation, experiments need to be done in
C57BL/6 mice as hosts using depleting anti-NK1.1 mAb in place of anti-CD 122 mAb. 
the deletion or inactivation ofNK cells is required, then the use ofanti-NK1.1 mAb plus
anti-CD8 mAb without DST should produce chimeric mice with high frequency.
As another possible interpretation, the anti-CD8 mAb injected into the host may
remove not only the indigenous population of CD8+ cells , but also the population from
the donor bone marrow that was introduced into the host. Several laboratories have
reported the existence of "facilitator" cells, a rare CD8+ bone marow subpopulation
from the donor that can enhance allogeneic hematopoietic stem cell engraftent
(120;121;203;204). The circulating anti-CD8 mAb in the host may be deleting these
donor facilitating cells required for stem cell engraftent in a non-myeloablated host.
CD4+ T cells have been proposed to be important in skin allograft surival using
DST and anti-CDl54 mAb by providing helper factors to induce alloantigen-activated
CD8+ T cell to undergo activation-induced cell death (138;139). In contrast, the addition
of anti-CD4 mAb to our chimerism protocol did not prevent hematopoietic engraftment
but it did lower the percentage of donor-origin cells in the PBMC when compared to
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controls. This observation supports the previous report that anti-CD4 mAb does not
prevent the establishment of hematopoietic chimerism in mice treated with anti-CDl54
mAb plus busulfan (179). Finally, as expected (142;143), increasing the dose of bone
marrow cells or adding minimal myeloablative conditioning to our protocol increased
both the frequency of mice engrafted as well as the level of engraftent.
An issue relevant to the utility of "multi-stage" transplantation tolerance induction
procedures in clinical medicine is the strngency with which the components of the
therapy need to be timed. We observed that our procedures were successful if initiated 1-
2 weeks before bone marow transplantation, but not 5 or fewer days before
transplantation. This observation has clinical implications as extended procedures are
usually not desirable for a number of reasons, such as the use of cadaver donors. Furher
research must be conducted to determine the reason for the timing requirement. Another
important clinical issue is the surrising discovery that the priming transfusion given after
the first injection of anti-CD 154 mAb need not be MHC-matched with the eventual bone
marrow donor. The clinical implication is obvious , in that the complex orchestration of
obtaining and delivering to a recipient a DST and bone marow and an organ for
transplantation can be greatly simplified. But the supposedly non-specific tolerance seen
after DST plus anti-CDl54 mAb treatment holds some cause for caution because of the
possibility of tolerance toward a pathogen. This concern has been examined by Welsh 
at. (205) who found that mice treated with DST and anti-CDl54 mAb are able to clear
LCMV infection successfully, suggesting that the treatment does not have detrimental
affects on the host' s viral immunity. But viral infections, both acute and chronic , have
126
been found to prevent allogeneic chimerism induction (206;207); whereas, prior viral
infection that has been cleared does not have any effect (207). So, in the clinical setting
precaution must be employed to avoid exposure to viral pathogens for the safety and
successful treatment of the patient. Another clinical concern is the thrombotic events
seen in human trials using anti-CDl54 mAb. In an effort to address this issue, one of the
highlights of the protocol discussed in this study is that the regimen used for chimerism
and tolerance induction is very short without requiring any fuher manipulations (i,
only 4 doses of anti-CD 154 mAb).
The use of immunosuppressive drgs is a standard therapy in the clinic when
dealing with any form of transplantation, including stem cell transplantation. Translation
of the chimerism protocol presented in this study to human patients wil undoubtedly
include some form of immunosuppression to ensure their safety and prevent loss of the
organ graft in case tolerance is not achieved. The effects of immunosuppressive drgs on
the effcacy of this protocol are unkown, but a recent study using costimulatory
blockade and low-dose irradiation has shown that calcineurin inhibitors prevent
chimerism and tolerance induction; whereas compatible immunosuppressive drgs, such
as rapamycin and mycophenolate mofetil, may facilitate in allogeneic stem cell
engraftment. Therefore, serious consideration should be made in the selection of
immunosuppressive drugs when used in conjunction with the chimerism protocol
discussed in this study,
In conclusion, I have developed an allogeneic chimerism protocol that
incorporates a technique that has been used in my lab to induce peripheral tolerance to
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condition the host to accept donor hematopoietic stem cells. But most importantly, the
induction of chimerism does not require any radiation pre-treatment or large number of
bone marow cells. In addition, by using the new synchimera model system, we are able
for the first time to analyze the mechanism necessary for the induction and maintenance
of allogeneic chimerism in a "normal" immune system. The key element to this system is
having a small trace population of self-renewing CD8+ alloreactive T cells within a
normal micro environment. The data presented here document directly that the
generation of allogeneic chimeras involves the peripheral deletion of high-affnity CD8
alloreactive T cells by DST and co stimulatory blockade, and supports the theory that
chimerism induces continued elimination of alloreactive cells by negative selection in the
thymus. The results further suggest that there is commonality to the generation of
peripheral and central tolerance and that the maintenance of transplantation tolerance wil
require either physical thymectomy or its biological equivalent-central tolerance
induction. As a final note, the protocol I have developed does not require host
myeloablative conditioning, appear not to lead to GVHD, and may not necessarly require
MHC matching of transfusion and bone marow-characteristics that make these
procedures highly attactive for translation to clinical medicine,
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